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In this work we established new transgenic Drosophila models for 
Parkinson’s (PD) and Huntington’s disease (HD), two incurable devastating 
human neurodegenerative diseases, which strongly compromise the patients’ 
motor abilities. Our Drosophila models are based on the transgenic 
overexpression of fluorescent-tagged versions of two human neuronal proteins 
extensively associated with these neuropathologies, but whose exact 
biological function is still unknown: alpha-synuclein (α-syn) for PD and 
huntingtin (Htt) for HD.  
Here, we investigated whether the subcellular localization of α-syn and 
the defective axonal transport of this protein is relevant to the development of 
PD. Using a Drosophila model for PD based on the overexpression of EGFP-
tagged versions of the wild-type and the familiar A30P mutant form of human 
α-syn, we observed a differential subcellular localization of the two versions 
of α-syn in the photoreceptors: while wild-type α-syn was enriched in pre-
synaptic terminals, α-syn A30P was distributed throughout the cytoplasm of 
the photoreceptors, both in cell bodies and axons. We have identified, by 
immunoprecipitation and mass spectrometry, the specific neuronal proteins 
interacting with wild-type and A30P α-syn, and by knocking-down the genes 
of these proteins we identified three candidates as neuronal modulators of α-
syn’s axonal transport and subcellular localization: Tomosyn, Spaghetti 
Squash, and Synaptotagmin 4. 
We also studied the role of N-terminal phosphorylation of mutant Htt in 
HD. We used our Drosophila model for HD, based on the overexpression of a 
mCherry-tagged version of the N-terminal truncated form of mutant human 
Htt, encoded by the exon 1 of Htt gene (Httex1). We analyzed the relative 
contribution of the phosphorylation state of each phosphorylatable residue in 
the first 17 amino acids of the N-terminal domain (NT17) towards Httex1 
aggregation and toxicity in our Drosophila model and in mammalian cells in 
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culture. We demonstrated that single phosphorylation events in NT17 and 
specific protein phosphatases can modulate mutant Htt aggregation and 
neurotoxicity, depending on the biological context. Our findings suggest that 
single phosphorylation events at NT17 could be a more effective therapeutic 
approach against HD. 
Taking advantage of our newly established Drosophila models for PD 
and HD, we also investigated the possible crosstalk between these two 
neuropathologies, by studying the interaction of α-syn and Htt, at the genetic 
and functional levels. We showed that α-syn and mutant Htt co-aggregate in 
vivo when co-expressed in Drosophila and produce a synergistic age-
dependent increase in neurotoxicity associated to a decline in motor function 
and life span. Our results suggest that the co-existence of α-syn and Htt in the 
same neuronal cells worsens aggregation-related neuropathologies, 
accelerating the disease progression. 
Finally, we wanted to test the therapeutic properties of 
mannosylglycerate (MG) in our Drosophila models for PD and HD. The 
biosynthesis of MG can be catalyzed by MG synthase (MGSD). We 
successfully generated transgenic lines expressing MGSD, but we could not 
detect the biosynthesis and accumulation of MG in Drosophila.  
We hope this work will contribute for a better understanding of the 
molecular and cellular bases of PD and HD and that our new Drosophila 
models for these pathologies may constitute one more useful platform 








Neste trabalho estabelecemos novos modelos transgénicos de 
Drosophila para as doenças de Parkinson (DP) e de Huntington (DH), duas 
doenças humanas neurodegenerativas devastadoras e incuráveis que afectam 
significativamente o controlo motor dos doentes. Os nossos modelos de 
Drosophila baseiam-se na sobrexpressão de duas proteínas neuronais 
humanas associadas a estas neuropatologias e para as quais a função biológica 
é desconhecida: alpha-synuclein (α-syn) para a DP e huntingtin (Htt) para a 
DH. 
Um dos nossos objectivos consistia em investigar se a localização sub-
celular da α-syn e o anormal transporte axonal desta proteína são relevantes 
no desenvolvimento da DP. Utilizando um modelo de Drosophila para a DP, 
baseado na sobrexpressão das formas “wild-type” e mutante A30P da α-syn 
fundidas com a “tag” fluorescente EGFP, observámos que o fenótipo relativo 
à localização sub-celular da α-syn é distinto para as duas formas da α-syn: a 
forma “wild-type” localiza-se predominantemente nos terminais pré-
sinápticos, enquanto que a mutante A30P distribui-se por todo o citoplasma 
dos fotoreceptores, tanto nos corpos celulares como nos axónios. Através de 
imunoprecipitação e espectrometria de massa, foi possível identificar as 
proteínas que interagem especificamente com as versões “wild-type” e 
mutante da α-syn e através do “knocking-down” dos genes que codificam para 
estas proteínas conseguimos identificar três candidatos a moduladores da 
localização sub-celular e do transporte axonal da α-syn: Tomosyn, Spaghetti 
Squash, and Synaptotagmin 4. 
Também estudámos o papel da fosforilação da porção N-terninal da Htt 
mutante na DH. Para isso, utilizámos o nosso modelo de Drosophila para a 
DH, baseado na sobrexpressão de uma versão truncada da porção N-terminal 
da Htt mutante, codificada pelo exão 1 do gene da Htt (Httex1). Assim, foi 
possível analisar, no nosso modelo de Drosophila e em células de mamífero 
em cultura, a contribuição relativa do estado de fosforilação de cada um dos 
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resíduos fosforiláveis nos primeiros 17 aminoácidos do domínio N-terminal 
(NT17) para os níveis de agregação e toxicidade da Httex1. Foi demonstrado 
que eventos únicos de fosforilação no NT17 e fosfatases especificas modulam 
efectivamente os níveis de agregação e neurotoxicidade da Htt mutante, de 
uma forma que é dependente do contexto biológico. Assim, os nossos 
resultados sugerem que eventos únicos de fosforilação no NT17 poderão 
constituir uma estratégia terapêutica mais eficaz contra a DH. 
Tirando partido dos novos modelos de Drosophila para as DP e DH 
estabelecidos neste trabalho, o possível “crosstalk” entre estas duas doenças 
foi também investigado, através do estudo da interacção genética e funcional 
da α-syn e Htt. Desta forma, demonstrámos que a α-syn e a Htt mutante, 
quando co-expressas em Drosophila, co-agregam “in vivo” e aumentam, de 
uma forma sinergística e dependente da idade, a neurotoxicidade, disfunções 
motoras e mortalidade. Assim, os nossos resultados sugerem que a co-
existência da α-syn e Htt nas mesmas células neuronais poderá exacerbar as 
neuropatologias relacionadas com a agregação de proteínas, podendo acelerar 
a progressão destas doenças. 
Por último, também pretendiamos testar as propriedadades terapêuticas 
do manosilglicerato  (MG) nos nossos modelos de Drosophila para as DP e 
DH. A biosíntese do MG pode ser catalizada pela MG sintetase (MGSD). Foi 
possível produzir linhas transgénicas a expressar MGSD, mas não 
conseguimos detectar a biosíntese e acumulação de MG em Drosophila. 
Esperamos que este trabalho possa contribuir para um melhor 
conhecimento das bases moleculares e celulares das DP e DH e que os nossos 
novos modelos de Drosophila para estas patologias constituam mais uma 
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1.1. Human neurodegenerative diseases 
Human neurodegenerative diseases are a heterogeneous group of 
devastating age-dependent disorders for which there is no cure or effective 
symptomatic treatments.  
These neuropathologies are characterized by the selective and 
progressive loss of specific neuronal cells. The clinical manifestations of 
each disease are determined by the region of the brain that degenerates 
(Table 1.1). Although most neurodegenerative disorders display an array 
of neural symptoms, they may be grouped and categorized in two major 
groups: movement disorders and dementias. Movement disorders are 
mainly characterized by the loss of motor control, in the form of tremor, 
chorea, akinesia, bradykinesia or ataxia, for example.  Parkinson’s disease 
(PD) and Huntington’s disease (HD) belong to this category, although they 
frequently show cognitive deficits and psychiatric problems concomitant 
to motor deficits [1]. Dementias are mainly characterized by a severe loss 
of cognitive function, as it occurs in Alzheimer’s disease (AD), fronto-
temporal dementia or dementia with Lewy bodies (LB). However, 
dementias can also be accompanied by motor symptoms [2]. 
 
Table 1.1. Clinical, pathological and biochemical features of neurodegenerative 







The genes responsible for many of the existing neurodegenerative 
diseases have been identified, and they can be genetically inherited in a 
recessive or dominant manner, depending on the disease. However, a high 
percentage of cases are sporadic, being their causes and the associated 
risks unclear. This is especially true for PD and AD, which are the two 
most frequent neurodegenerative disorders [4]. Approximately 95% of PD 
cases appear without a family history or a specific mutation [5]. 
The misfolding, aggregation and accumulation of neuronal proteins 
into protein inclusions constitutes a common hallmark to most human 
neurodegenerative diseases (Fig. 1.1). 
 
Figure 1.1. The formation of protein aggregates constitutes a common hallmark of 
human neurodegenerative diseases. Although the cellular and subcellular 
localization and the protein composition of these aggregates may be different, its 
ultrastructure seems to be similar and enriched in fibrillar polymers (center). 
Adapted from [3]. 
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Protein aggregates are visible in cells and tissues with basic 
microscopic techniques, and still constitute the main post-mortem 
diagnostic tool for neurodegenerative disorders, including PD [6, 7]. 
However, protein aggregation is a dynamic process that involves 
seeding/nucleation mechanisms starting with the formation of small 
soluble oligomeric species. This intermediate state of aggregation has a 
high tendency to become stabilized by the formation of an oligomeric 
β-sheet structure, which by incorporation of additional monomers gives 
rise to protofibrils and finally to cross-β amyloid-like fibrils. Therefore 
protein oligomers constitute the nucleus material from which protein 
aggregates start forming and growing, giving rise to the typical protein 
amyloid-like inclusions observed in AD, PD and HD [8-10]. The generic 
term “amyloid” is commonly used to refer to the cross-β structure of the 
aggregates with binding affinities to Congo red and thioflavin S dies. 
If large protein aggregates are the toxic entities responsible for 
neurodegeneration or a protective response against other toxic species is 
still widely debatable. There are several reports supporting a neurotoxic 
role for fibrillary aggregates, in which large aggregates containing 
misfolded proteins may interfere with the normal function of other 
neuronal proteins, by sequestering them in these aggregates.[11-16].  
However, the hypothesis that the large protein aggregates may 
constitute a cellular defense mechanism against more toxic smaller 
aggregates, or monomers, dimers, oligomers and protofibrils, has lately 







Figure 1.2. Schematic representation of the process involved in the formation of 
amyloid inclusions in human neurodegenerative diseases. Several factors (such as, 
mutations, environmental stress and aging) may contribute to the misfolding and 
aggregation of native soluble monomer proteins. These aggregated monomers can 
adopt abnormal conformational structures, generating different intermediate 
species of aggregates (dimers, oligomers and protofibrils). A variety of complex 
pathways eventually give rise to large amyloid plaques, enriched in β-sheet fibrils, 
a histopathological hallmark of most human neurodegenerative diseases. These 
large aggregates were originally considered neurotoxic but accumulating 
evidences suggest they may have a cytoprotective role. Adapted from [17]. 
 
For example, in AD the cognitive impairment is not correlated with 
the density of Aβ plaques [18, 19], being the concentration of soluble Aβ 
much strongly correlated with the severity of the disease [20-22]. 
Equivalently, in PD LB could have a protective role, since the neurons 
where these inclusions are mostly found are healthier than adjacent 
neurons with no inclusions [23]. Soluble oligomeric species are often able 
to cross membranes, move between cell compartments and outside the cell, 
interacting with several macromolecules and consequently interfering with 




The role of protein aggregates in neuropathologies remains poorly 
understood and more studies are necessary to clarify if these aggregates 
and the correspondent molecular mechanisms associated to protein 




1.2.  Parkinson’s disease 
1.2.1. Epidemiology, symptoms and general molecular features 
PD was firstly described in 1817 by James Parkinson as the 
“shaking palsy” (Figure 1.3). The most prominent clinical symptoms are 
related to motor functions: tremor, bradykinesia (slowness of movement), 
rigidity and postural instability. In later stages, cognitive and behavioral 
functions may also be affected. Post-mortem analyses of PD brains 
revealed that PD is the second most frequent human neurodegenerative 










Figure 1.3. First scientific description of Parkinson’s disease (PD) by James 
Parkinson in “An essay on the shanking palsy, 1817” and the illustration of this 
pathology by William Richard Gowers published in “A manual of diseases of the 
nervous system, 1886”. 
 
PD is primarily an age-related disease and the number of affected 
individuals is expected to increase significantly in the next decades as 




PD, and neurodegenerative disorders in general, constitutes an 
enormous socio-economic burden. For example, the current cost of the 
treatments for patients with PD in United States is higher than 14 billion 

























Figure 1.4. Projection of the grow rates (on the left) and of the number of patients 
suffering from Parkinson’s disease (PD) (on the right) from 2005 until 2030. 








The presence of intraneuronal inclusions in surviving neurons, 
called LB, constitutes one of the hallmarks of post-mortem brain analysis 
of patients suffering from PD (Fig. 1.5). In PD the region of the brain most 
affected by degeneration are the dopaminergic (DA) neurons from the 
substantia nigra pars compacta (SNpc). 
 
Figure 1.5. Lewy body (LB) and other cytoplasmic inclusions (CI) enriched in α-
synuclein (α-syn) within the neurons of the dopaminergic neurons (DA) from 
substantia nigra pars compacta (SNpc) constitute an hallmark in Parkinson’s 
disease (PD). Extracted from [28]. 
 
PD is mostly sporadic, with familial forms constituting 
approximately 10% of affected individuals. Eleven genes were associated 




Table 1.2. Genetic loci associated to Mendelian Parkinson’s disease (PD). 
Extracted from [29]. 
 
Four of these loci are causative of autosomal dominant PD: SNCA, 
encoding α-synuclein (α-syn); LRRK2, encoding leucine-rich repeat kinase 
2; VPS35, encoding Vacuolar protein sorting 35 homolog and EIF4G1, 
Eukaryotic translation initiation factor 4-gamma 1. 
SNCA gene was the first to be identified as being associated to PD 
and encodes α-syn, a neuronal protein of unknown function. Because 
α-syn is the principal component of the LB, it is considered a major player 
in this neuropathology. Several mutations have been mapped to SNCA 
locus, including missense mutations and genomic duplications or 
triplications, which account for the second most common cause of 
dominant PD. 
Mutations in LRRK2 are the most common genetic cause of 
dominant PD, accounting for 10% of all familial forms. Lrrk2 is a 
cytosolic protein with two predicted enzymatic domains, one with GTPase 
and another with kinase activity. Although the exact biological function is 
unknown, it has been associated with neurite formation and growth, 




34]. More recently, mutant versions of VPS35 and EIF4G1 were linked to 
autosomal PD. VPS35 is one of the components of the tripartite complex 
retromer, involved in the endosomal-lysosomal trafficking. The mutant 
forms of VPS35 may affect the development of DA neurons through the 
Wnt pathway [35, 36] and abnormal iron accumulation in the brain by the 
DMT1 pathway [37, 38]. EIF4G1 is involved in mRNA translation [39]. 
Although the familial forms of PD constitute a minority, the 
identification of PD loci has enabled the study and characterization of 
some of the molecular mechanisms of idiopathic PD. For example, mutant 
forms of Parkin, Pink 1 and F-box only protein 7 have been implicated in 
the dysregulation of normal mitophagy [40-43], and mutations in the genes 
encoding Lrrk2 and VPS35 may disrupt normal processes of protein 
degradation by the autophagy/lysosomal pathway, ultimately leading to the 
accumulation of cytotoxic misfolded proteins and cell death [44-47].  
 
 
Besides the classical linkage analysis, genome-wide association 
studies (GWAS) allowed to identify risk loci associated to sporadic forms 
of PD (Table 1.3). However, the specific roles of these genes in the 
molecular basis of PD remain unknown. 
Whether PD is familiar or idiopathic, and regardless the mutations 
and genes involved, α-syn is the main constituent of LB in the brain, being 






Table 1.3. Risk loci identified by several genome-wide association studies 







1.2.2 α-Synuclein: a major player in Parkinson’s disease 
The synuclein family is constituted by α-, β- and γ-syn, but only α-
syn has been found to be associated to human neurodegenerative diseases. 
α-Syn is a small neuronal protein composed by 140 amino acids, and 
encoded by the human SNCA gene in the chromosome 4 (Figure 1.6). 
 
 
Figure 1.6. α-Synuclein (α-syn) is a major player in Parkinson’s disease 
pathogenesis. (A) α-syn is encoded by SNCA gene, located on chromosome 4. (B) 
From the 6 exons comprising SNCA, only the last 5 encode for α-synuclein 
protein, which is composed by 140 amino acids. (C) Schematic representation of 
the different domains of α-syn and the localization of the familial mutations A30P, 





Several mutations segregated with PD have been already mapped to 
the SNCA locus. The missense mutation A53T was mapped in 1997 [50]. 
Subsequently two additional missense mutations were mapped: A30P and 
E46K [51, 52]. These missense mutations are located in the N-terminal 
domain of α-syn, involved in the binding to membranes, and induce an 
increase in the propensity of this protein to misfold and form fibrillar 
aggregates enriched in β-sheet structure [53-55]. More recently, the H50Q 
[56] and G51D [57] missense mutations were also identified. The H50Q 
mutation stabilizes α-syn fibrils, significantly increasing the aggregation 
rate and the ability of this protein to form amyloid inclusions, while the 
G51D mutation slowdowns α-syn aggregation, but both mutations 
increased the toxicity [58-61]. Genomic duplication or triplication of the 
SNCA locus, which increases α-syn expression, also causes a form of 
autosomal dominant PD [62-64]. The SNCA dosage is inversely correlated 
with the age of onset and directly correlated with the severity of the 
disease [65-67]. Post-mortem analysis of sporadic PD midbrain tissues 
revealed that the total mRNA levels for α-syn were significantly increased, 
when compared to control brains, further highlighting the relevance of the 
levels of expression of this protein in PD [68]. 
GWAS indicated that variations at the SNCA locus are also strongly 
correlated with the sporadic forms of PD, corroborating the importance of 
α-syn in the etiology of this neuropathology (Fig. 1.7). In fact, hundreds of 
single nucleotide polymorphisms (SNPs) within the SNCA locus have 
been shown to increase susceptibility to PD (based on PDgene database – 
http://www.pdgene.org). Moreover, polymorphisms in the promoter region 
of SNCA have been also linked to PD [69]. The expansion of the 
polymorphic dinucleotide repeat REP1 increases α-syn expression, thus 




SNCA may also affect the stability and the alternative splicing of α-syn 
mRNA transcripts. Indeed, at least 6 different transcripts of this gene exist. 
Besides the transcript encoding the full-length protein (140 aa), 5 truncated 
forms have been described. One of these truncated forms (112 aa) has been 
associated to LB formation and neurotoxicity [72].  
 
Figure 1.7.  Variations at the SNCA locus, identified by genome-wide association 
studies (GWAS), associated to the sporadic forms of Parkinson’s disease (PD). 
(A) The REP1 dinucleotide repeat, in the promoter region, regulates the levels of 
SNCA expression; Three single nucleotide polymorphisms (SNP) that may alter 
transcripts’ splicing and stability, and that are highly associated with PD, are also 
indicated (in green). (B) Four isoforms of SNCA generated by alternative splicing 






1.2.3 The vulnerability of dopaminergic neurons in Parkinson’s 
disease 
The specificity of the neuronal subpopulations that are mostly 
affected and degenerate in each neurodegenerative disease raises a 
fundamental question: are the insults specifically induced in those neurons 
or are there specific cellular and molecular characteristics of the affected 
neuronal subpopulations that render them more vulnerable to the insults? 
In the case of PD, the most affected neuronal population is the DA neurons 
from SNpc that project their axons to the striatum (Figure 1.8). 
 
 
Figure 1.8. The dopaminergic (DA) system and the nigrostriatal pathway. The DA 
neurons from substantia nigra pars compacta (SNpc), the most vulnerable 
neuronal population in Parkinson’s disease (PD), project their axons to the 
medium spiny neurons (MSN) from the striatum, constituting the nigrostriatal 
pathway, which plays a crucial role in the motor control. 
 
The death of these neurons, and the consequent impairment of the 
nigrostriatal DA pathway, is the cause of the motor symptoms observed in 
PD. It is especially intriguing if we consider that from all the types of DA 




neurons from ventral tegmental area (VTA), the DA neurons from SNpc 
are the most vulnerable in PD. 
Protein misfolding and aggregation, dysregulation of the ubiquitin 
proteasome system, mitochondrial dysfunction and oxidative stress are not 
exclusive of DA neurons, but are present in most areas of the PD brain 
[73-75].  The difficulty in justifying the vulnerability of the DA neurons 
from SNpc also persists when considering the familial forms of PD. The 
expression of genes linked to this pathology is not specific and limited to 
the DA neurons. For example, SNCA is ubiquitously expressed in the 
central nervous system (CNS) at high levels, being also present in other 
non-neuronal tissues [76]. 
 The exposure to the neurotoxins 6-OHDA and MPTP specifically 
induces neurodegeneration of the DA neurons from SNpc, and for this 
reason they have been largely used as pharmacological models of PD. The 
selectivity of these neurotoxins is explained by the fact that their 
internalization into the cells is dependent on Sodium-dependent dopamine 
transporter (DAT), which is only expressed in the DA neurons. 
Importantly, DAT is expressed at higher levels in SNpc than in the VTA 
[77]. However, this explanation cannot be applied to other drugs that 
induce PD-like pathology and symptoms, as is the case of the toxins 
rotenone and paraquat, widely used as pesticide and herbicide, 
respectively. Rotenone affects the mitochondrial function by inhibiting the 
mitochondrial complex I, while paraquat induces oxidative stress, both 
insults not being specifically targeted to the DA neurons from SNpc. 
Bolan and Pissadaki [78] and by Brichta and Greengard [79] have 
previously reviewed several particular determinants that put the SNpc DA 
“on the edge” of the risk to degenerate in PD.  Some of these 
characteristics are related with the neuroanatomy of the nigrostriatal 
pathway. The axons projecting from the SNpc DA neurons to the striatum 
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are unmyelinated and extremely long, having a total cumulative length of 
70 cm [80] and the estimated number of synapses established by these 
axons is equally massive (200.000 – 400.000) [81, 82]. These unique 
morphological features impose extreme bioenergetic demands, increasing 
the metabolic needs of the SNpc DA neurons to maintain the membrane 
potential, generate action potentials and enable synaptic transmission [83]. 
These exceptional energetic demands could make them especially 
susceptible to insults of any sort, including environmental and genetic 
factors [78].  
Another important risk factor inherent to the DA neurons is the 
oxidation of dopamine and the consequent generation of reactive oxygen 
species [84]. Dopamine is a potentially dangerous neurotransmitter within 
the cells, as it easily undergoes oxidation generating dopamine-derived 
quinones and other toxic molecules (Figure 1.9). Furthermore, cytoplasmic 
accumulations of misfolded α-syn may affect the secretory pathway by 
blocking the normal ER-Golgi traffic and thus exacerbating the deleterious 






Figure 1.9. Schematic representation of the molecular mechanisms associated to 
the toxic properties of the dopamine-derived quinones (DAQ). Extracted from 
[86]. 
 
The investigation of the specific cellular and molecular determinants 
of the differential susceptibility of the DA neurons from SNpc in PD has 
proven to be very challenging but holds great potential for the discovery of 
new therapeutic targets.  
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1.3. Huntington’s disease 
1.3.1. Epidemiology, symptoms and general molecular features 
HD is the most common genetically inherited neurodegenerative 
disease, belonging to the group of polyglutamine (polyQ) pathologies and 
affecting approximately 5 to 10 per 100.000 individuals in the Caucasian 
population [87-89]. It is caused by a mutation in the first exon of the 
unconventionally large IT-15 gene (67 exons), which encodes a protein 
called huntingtin (Htt). 
Mutant Htt misfolds and accumulates into amyloid-like 
proteinaceous aggregates in the medium spiny neurons (MSN) from the 
striatum, being the most common post-mortem histopathological feature 
(Fig. 1.10). 
 
Figure 1.10. Post-mortem analysis of patients’ brains with Huntington’s disease 
(HD) show intranuclear inclusions (INI) and cytoplasmic inclusions (CI) 
containing mutant Huntingtin (Htt) accumulated. Extracted from [28]. 
Neurons from the thalamus, hippocampus and cortex also 
degenerate, accounting for the typical symptoms observed in patients: 
involuntary movements (chorea), dementia and psychiatric problems 






1.3.2. Huntingtin: the monogenic cause of Huntington’s disease 
Since 1993, when the Htt gene was mapped to the short arm of 
chromosome 4, intense research has been conducted aiming to identify the 
biological function of Htt, as well as its role in the HD pathogenesis. 
The disease-associated mutation of Htt occurs in the N-terminal 
region of Htt and consists of an abnormally high number of cytosine-
adenine-guanine (CAG) triplet repeats. The expanded CAG repeats are 
translated to an extended stretch of glutamines commonly called polyQ 
tract [90, 91]. Htt is an unusually large protein, constituted by 3144 amino 
acids (approximately 350 kDa). However, the N-terminal portion of 
mutant Htt (exon 1) harboring the polyQ tract (Fig. 1.11) is sufficient to 
produce HD phenotypes in vivo [92-97]. For this reason, most of the model 
systems established to study HD in vitro and in vivo are based on the 
expression of mutant versions of the exon 1 of Htt gene (Httex1). 
 
 
Figure 1.11. Human huntingtin (Htt) is a large protein constituted by 3142 amino 
acids. The N-terminal domain of this protein, encoded by the exon 1 (Httex1), is 
highly enriched in the protein inclusions from post-mortem analysis of HD brains. 
The N-terminal domain of Htt is constituted by the first 17 amino acids (NT17), 





The polyQ tract of wild-type Htt contains between 6 and 29 
glutamines, while mutant alleles associated to HD contain over 36 
glutamines. The longest polyQ tract ever detected in an HD patient was 
constituted by 130 glutamines [98]. Individuals carrying intermediate 
alleles containing a range of 29-35 glutamines are healthy and totally 
asymptomatic. However, due to the meiotic instability of the CAG repeats, 
these individuals have a very high probability to transmit a pathological 
polyQ expansion over 36 glutamines to their offspring, especially from the 
paternal side [99, 100]. 
The number of glutamines, which is responsible for approximately 
70% of the variance, is inversely correlated with the age of onset of the 
disease, with longer polyQ tracts inducing an earlier and more severe onset 
of the pathology [101]. The mean age of HD onset is 38 years, although it 
may vary between the ages of 25 and 70 years. PolyQ tracts containing 
over 55 glutamines (5% of all cases) produce Juvenile HD, where the onset 
can start before the age of 20 years [102]. The mean duration of the disease 
is 17-20 years and patients usually die from pneumonia or suicide [103]. 
Despite the efforts made to date, there is still no cure for HD and the 
drugs available can only treat the symptoms. For the development of 
effective treatments for HD, it is essential to understand the cellular and 
molecular mechanisms underlying this pathology. 
The exact biological function of Htt is unknown, but it was shown to 
possess an indispensable anti-apoptotic role [104, 105]. There is also 
evidence that Htt is essential for normal development, as Htt-null mutant 
mice die as embryos at day 7.5 [104, 106, 107]. Surprisingly, Htt is 
dispensable for Drosophila development, but it is crucial for normal long-
term mobility and survival in adult flies [108].  Htt interacts with a high 




functions, such as endocytosis, neurotransmission, transcriptional 
regulation, axonal transport and apoptosis [109-111]. Htt could act as 
scaffold, responsible for bringing together its protein partners and for 
coordinating the transfer of information among different subcellular 
compartments, namely between the nucleus and cytoplasm [111]. Htt 
could also act as a scaffold protein in selective autophagy by promoting 
cargo recognition and autophagy initiation [112].  
The expansion of the polyQ tract promotes conformational changes 
in Htt that dramatically increase its propensity to misfold and aggregate. 
Htt aggregation could affect the interaction with its neuronal partners and 
disturb the normal function of Htt and Htt-interacting proteins. This 
suggests the involvement of both toxic gain-of-function and loss-of-







1.3.3. Medium spiny neurons vulnerability in Huntington’s disease 
Although Htt is ubiquitously expressed throughout nervous system 
and other peripheral tissues (namely, testes, liver, heart and lungs) the 
pathological effects are predominantly induced in specific neuronal 
populations of the brain, especially the MSN neurons from the striatum 
[113-118]. The fact that mutant Htt affects this particular neuronal 
population points to the possible relevance of cell- or tissue-specific 
factors in HD pathogenesis, beyond the expanded polyQ tract.  
Brain-derived neurotrophic factor (BDNF) is a possible determinant 
of the increased susceptibility of MSN neurons to neurodegeneration in 
HD. BDNF is a neurotrophin necessary for the development, survival and 
proper function of the striatal neurons. Deficient BDNF signaling in the 
striatum, presumably caused by mutant Htt, has been pointed as strong 
candidate to be a molecular determinant and modulator in HD 







Figure 1.12. The dysregulation of the intracellular transport of brain-derived 
neurotrophic factor (BDNF), induced by mutant Htt (muHtt) has been pointed as 
one of the determinants of the increased vulnerability of the striatum neurons in 
Huntington’s disease (HD). (A and B) Wild-type Htt (wtHtt) is involved in the 
vesicular transport of BDNF along microtubules. Depending on the 
phosphorylation state of wtHtt the vesicles undergo either retrograde transport 
(left arrow), mediated by dynein and dynactin, or anterograde transport (right 
arrow), mediated by kinesin 1. (B) The muHtt binds more tightly to huntington-
associated protein 1 (HAP1), inducing an inefficient transport of the vesicles 





1.4.  Modeling Parkinson’s and Huntington’s diseases in Drosophila 
The establishment of animal models is one of the most useful 
approaches to study the pathogenic mechanisms of human diseases at the 
molecular, cellular, organic and functional level. Drosophila 
melanogaster, commonly known as fruit fly, is a powerful genetic model 
organism that has been used to study complex biological phenomena for 
more than a century, including human neurodegenerative diseases [121].  
The identification of genes associated to the familial forms of PD 
and HD in the last decade allowed the establishment of animal models for 
these pathologies, which are essential to investigate the early pre-
symptomatic stages of pathogenesis and to test new drug candidates. 
One of the key factors that contributed to the great success of 
Drosophila as a model organism to study human pathologies is the very 
high degree of conservation with mammals, since approximately 75% of 
disease-related loci in humans have at least one Drosophila homologue 
[122]. Drosophila also offers a great number of potent genetic tools, it has 
a very well-known anatomy and has short life cycle and life-span. Finally, 
the central nervous system of invertebrates and vertebrates shares a 
common evolutionary origin. Flies have a complex nervous system 
capable of learning and coordination of intricate behaviors, and there is a 
significant degree of genetic and functional conservation between the fly 
central complex and the human basal ganglia, which is the region 
primarily affected in PD and HD [123]. Such homology constitutes an 
undeniable advantage to model and study these and other human 
neurodegenerative diseases. 
 In order to model a human neurodegenerative disease in flies, it is 
necessary to express in this organism the human genes associated with this 




Drosophila is by using the binary GAL4-dependent upstream activating 
sequence (GAL4/UAS) system [124] (Fig. 1.13). 
 
 
Figure 1.13. The GAL4/UAS system, used for overexpression of proteins in 
Drosophila, is a binary system which allows for the ectopic expression of genes of 
interest in a specific tissue or cell type. Two transgenic fly lines are created: the 
UAS line, in which the gene of interest is placed downstream of a UAS (Upstream 
Activating Sequence) domain, where the yeast transcriptional activator GAL4 
binds; and the GAL4 line (driver), which expresses Gal4 under the control of a 
tissue specific promoter. The gene encoded in the UAS line is only activated when 
this line is crossed with the GAL4 line. In our study we generated UAS lines 
encoding for α-synuclein (α-syn) and huntingtin (Htt) and we used pan-neuronal, 
dopaminergic and photoreceptor drivers. 
 
The gene of interest is subcloned into an UAS expression construct, 
which is microinjected into fly embryos to establish transgenic lines. The 
protein of interest is expressed in a targeted way by performing the genetic 
cross of the UAS line with a Gal4 line that expresses the yeast 
transcriptional co-activator GAL4 in a specific tissue or cell type. 
Expression is therefore controlled both in time and space, depending on 
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the presence of GAL4 in cells and tissues. Many cell-type and 
developmentally regulated GAL4 lines, commonly called “drivers”, are 
readily available from Drosophila public stock centers (e.g. Bloomington 
Drosophila Stock Center at Indiana University). So, the effect of 
expressing a human transgene in many different tissues and at various 
developmental stages can be assayed without creating many independent 
transgenic lines. The GAL4/UAS system is especially useful when one 
aims to study the mechanisms of toxicity of human genes linked to the 
disease which are absent in the Drosophila genome, as is the case of α-syn. 
In the first Drosophila model of PD, transgenic flies expressing 
wild-type or two familial mutant forms (A30P and A53T) of human α-syn 
in the brain reproduced key features of PD, including LB-like inclusions 
(Fig. 1.14), selective degeneration of DA neurons, and abnormalities in the 
locomotor behavior [125]. Actually, Drosophila reproduced PD 
phenotypes better than mice models of the disease. 
 
 
Figure 1.14. In Parkinson’s disease (PD), α-synuclein (α-syn) accumulates in 
cytoplasmic inclusions (Lewy bodies), as it is shown in a brain section from a 
patient (left). These protein aggregates, which constitute a hallmark of PD, are 






However, in another report, missexpression of α-syn in the 
Drosophila CNS did not cause death of the DA neurons [127]. The 
inconsistency of the results from these independent studies may result 
from the use of different technical approaches. Therefore, there is the need 
for more independent studies in order to clarify some of these 
inconsistencies and to generate Drosophila models that consistently 
reproduce the key phenotypes resembling PD conditions. 
Concerning HD, Drosophila models show the essential features 
associated to the pathology, such as progressive neurodegeneration [128], 
motor deficits, protein inclusions in cytoplasm and nucleus (Figure 1.15) 
and a correlation between polyglutamine repeat length, age of onset and 
severity of the phenotypes [129]. 
 
 
Figure 1.15. In Huntington’s disease (HD), mutant huntingtin (Htt) typically 
accumulates in cytoplasmic and/or nuclear inclusions (arrows) in the brain. These 
inclusions are revealed by immunohistochemistry in post-mortem analyses of both 








In this work we have established new transgenic Drosophila models 
for PD and HD, based on the overexpression of wild-type and mutant 
versions of α-syn and Htt (Fig. 1.16). 
 
 
Figure 1.16. We generated UAS transgenic lines encoding fluorescent-tagged 
versions of two human proteins associated with Parkinson’s (PD) and 
Huntington’s diseases (HD). For PD we generated constructs of human α-
synuclein (α-syn) fused to EGFP and we used a wild-type (WT) and a familiar 
mutant form (the missense mutation A30P) of this protein. For HD we generated 
mCherry-tagged versions of a wild-type form with 19 glutamines (19Q) and a 
mutant form containing 97 glutamines (97Q) of human huntingtin (Htt). 
 
For the PD model, we used the missense mutation A30P, associated 
to familial cases of the disease; and for the HD model, we used wild-type 
and mutant forms of Htt, with 19Q and 97Q in the polyQ tract, 
respectively. These proteins were fused to fluorescent tags (EGFP for α-
syn and mCherry for Htt), allowing  microscopy and co-localization 
studies in either “live” or fixed biological materials. 
Taking advantage of the Gal4/UAS system, we were able to induce 
targeted expression of these proteins in different neuronal tissues of 
interest, such as in the whole nervous system, using the pan-neuronal 
driver Elav-Gal4, in the eye retina, using the sGMR-Gal4 driver and in the 








Figure 1.17. Targeted expression of EGFP-tagged α-synuclein using the 
Gal4/UAS system. Confocal microscopy images of adult flies expressing α-
synuclein-EGFP in different tissues: (A) in the whole-brain, using the pan-
neuronal driver Elav-Gal4; (B) in the photoreceptors, using the GMR-Gal4 driver; 
(C) in the dopaminergic (DA) neurons, using the TH-Gal4 driver. 
 
Throughout our study, depending on the specific questions and on 
the particular experiments to be done, we induced the targeted expression 
of the proteins of interest in different tissues, such as the whole brain, the 
eye photoreceptors or the DA neurons. The DA neurons constituted one of 
our favorite neuronal populations to study PD and HD in our Drosophila 
models, being the TH-Gal4 driver extensively used in our study. This 
driver expresses Gal4 under the control of the promotor region of tyrosine 
hydroxylase (TH) gene. TH is the enzyme that catalyzes the rate-limiting 
step of dopamine biosynthesis and is specifically expressed in all DA cells.  
The DA neurons, besides being the neuronal cell type directly 
affected in PD, the axons of the DA neurons constitute the main input to 
the MSN from the striatum, affected in HD. The DA system in mammals is 
involved in the control of locomotor behavior, motivational states and 
cognitive function, all of them impaired to different degrees in PD and 
HD. Furthermore, the impairment of particular behaviors, such as the 
initiation of voluntary actions  in mammals has been correlated with the 
malfunction of specific subpopulations of DA neurons, namely the ones 
involved in the nigrostriatal pathway [130, 131].  
General Introduction 
 33 
Drosophila DA system is well characterized by means of dopamine 
and anti-Tyrosine Hydroxylase (TH) immunoreactivity, enabling the 
characterization of several DA clusters which were named according to 
their anatomical localization in the brain: paired posterior lateral 1 and 2 
(PPL1 and PPL2); paired posterior medial 1 and 2 (PPM1/2); paired 
posterior medial 3 (PPM3); paired anterior lateral (PAL), and paired 
anterior medial (PAM). (Fig. 1.18) [132-134]. Similarly to mammals, 
Drosophila DA system is also involved in the modulation and control of 
locomotor behavior. Furthermore, specific subset of DA neurons are 
especially vulnerable to neurodegeneration and to induce motor deficits in 
the context of PD, which is equivalent to the situation observed in humans 
[135, 136]. 
For these reasons, we consider Drosophila DA neurons a very 
useful and adequate system to model and study human neurodegenerative 










Figure 1.18. The dopaminergic (DA) system in Drosophila. The DA neurons are 
grouped in several clusters in the Drosophila adult brain. In (A) and (C) are shown 
confocal pictures of adult brains expressing GFP-tagged mCD8 under the control 
of TH-Gal4 driver to label the DA neurons and immunostained with anti-nc82 to 
label the generic anterior and posterior neuropil structures. In (B) and (D) are 
shown schematic representations of the cell bodies and axonal projections from 
DA neurons, which are grouped in 6 distinct clusters: paired 
posterior lateral 1 and 2 (PPL1 and PPL2); paired posterior medial 1 
and 2 (PPM1/2); paired posterior medial 3 (PPM3); paired anterior 




1.5. Main goals 
Using our newly established Drosophila models, we were interested 
in the study of three different particular aspects that we believe to be 
relevant to the molecular pathogenesis of PD and HD: 
 the molecular determinants of the subcellular localization of α-syn 
in PD (Chapter II) 
 the effect of N-terminal phosphorylation in the aggregation and 
toxicity of Htt in vitro and in vivo (Chapter III) 
 the possible crosstalk between PD and HD molecular mechanisms, 
by studying the genetic and functional interaction between α-syn 
and Htt (Chapter IV) 
Additionally, we tried to identify new potential therapeutic 
compounds for PD and HD, being particularly interested in the putative 
therapeutic effect of mannosylglycerate (MG) in our Drosophila models of 
neurodegeneration (Chapter V). MG is a compatible solute, i.e. a substance 
compatible with the cellular metabolism that accumulates in the cytoplasm 
to balance external osmotic pressure. These properties confer potential 
neuroprotective effects to this compound in the context human 
neurodegenerative diseases, as previously shown by our collaborators 
using a yeast model for PD [137]. 
We believe this work will contribute to a better understanding of the 
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α-Synuclein (α-syn) is a neuronal protein highly enriched in the pre-
synaptic nerve terminals, which has been extensively associated to a group 
of neurodegenerative diseases called synucleinopathies, being Parkinson’s 
disease (PD) the most common pathology from this group. Despite all the 
efforts, the biological function of α-syn remains unclear. However, 
accumulating evidences support an important role for α-syn in 
neurotransmission, being the dysregulation of α-syn normal function at the 
synapses one of the possible causes for neurodegeneration. PD is mostly 
sporadic, but the existence of familial forms of the disease, namely the 
ones caused by mutations in the α-syn’s locus, has enabled in vivo studies 
by the generation of animal models for this pathology.  In this work, we 
established a new Drosophila model for PD, based on the expression of 
EGFP-tagged versions of the wild-type and the A30P mutant form of α-
syn in the photoreceptors. We observed mislocalization of α-syn A30P 
mutant form in the photoreceptors, comparing to the wild-type form. In 
order to investigate the molecular mechanisms relevant for the synaptic 
localization of α-syn we identified, by co-immunoprecipitation (Co-IP) 
and mass spectrometry, specific protein interactors for the wild-type and 
A30P mutant forms of α-syn. Subsequently, using the identified protein 
interactors, we performed an RNAi reverse genetic screen which enabled 
us to identify three candidate proteins (Tomosyn, Spaghetti Squash, and 
Synaptotagmin 4) as specific modulators of α-syn’s axonal transport and 





α-Synuclein (α-syn) is a small (140 aa) neuronal protein expressed 
in several regions of the vertebrates’ brain and highly enriched in the 
presynaptic nerve terminals.  
During the last two decades, several studies have demonstrated the 
involvement of α-syn in synucleinopathies, a group of neurodegenerative 
diseases in which α-syn aggregation and accumulation constitutes a 
common pathological hallmark. The three most common pathologies 
belonging to this group are: Parkinson’s disease (PD), dementia with Lewy 
bodies and multiple system atrophy. 
Specifically for PD, several mutations in the α-syn locus have been 
identified, constituting the second most common cause of familial 
dominant PD. These mutations include genomic duplications and 
triplications [1, 2] and the point mutations A30P, E46K, H50K, G51D, 
A53E and A53T [3-8]. Additionally, genome-wide association studies 
(GWAS) revealed that polymorphisms in the α-syn gene are also 
associated to the sporadic forms of PD, increasing the susceptibility to 
develop the disease [9]. 
The identification of α-syn as one of the major players in PD 
generated great interest in the scientific community to unveil the biological 
role of this protein in neuronal cells. Despite all the efforts, the exact 
biological function of this protein in neuronal cells as well as its relevance 
for the molecular mechanisms associated with neurodegeneration are still 
very unclear. 
Nevertheless, several studies suggest an important role of α-syn in 
the maintenance and normal function of synaptic membrane processes and 
in promoting the assembling of the presynaptic Soluble N-ethylmaleimide-
sensitive factor Attachment protein Receptor (SNARE) complex involved 
in the release of neurotransmitters [10]. The highly acidic C-terminal 




domain of α-syn directly binds to the N-terminal sequence of 
synaptobrevin-2, one of the proteins of the SNARE complex, promoting 
the SNARE complex assembling (Fig. 2.1) [11].  
 
Figure 2.1. The role of α-synuclein (α-syn) in neurotransmission by promoting the 
SNARE complex assembly. (A) The C-terminal domain of α-syn interacts with 
the N-terminal domain of synaptobrevin (VAMP) priming the assembling of the 
SNARE complex. (B) The assembling of the SNARE complex proceeds with the 
interaction of several other proteins, such as Hsc70, SNAP-25, SGT and CSPα. 
(C) The assembly of the SNARE complex promotes the fusion of the synaptic 
vesicles with the pre-synaptic membrane and the release of the neurotransmitters 









α-Syn is involved  in the SNARE complex assembly and has a 
protective effect in the massive neurodegeneration and synaptic 
dysfunction induced by a deficiency in CSPα, a synaptic protein with co-
chaperone activity [13-15]. Additional works have been pointing to the 
importance of α-syn in the synapses, namely those showing a role for 
α-syn in the regulation of the synaptic vesicle pool size and 
neurotransmitter release [16-18].  
Although these studies point to an important and beneficial function 
of α-syn, missense mutations or the long-term overexpression of α-syn 
may impair its function and render misfolded and/or toxic forms of α-syn, 
typically associated with PD and other synucleinopathies. All the familial 
point mutations associated to PD have been mapped in the N-terminal 
portion of α-syn and it has been demonstrated that these mutations affect 
the ability of α-syn to bind to biological membranes. In the specific case of 
the A30P mutation, several works have demonstrated less binding of α-syn 
to membranes [19-21]. A previous study showed that the A30P mutation 
changes the subcellular localization of α-syn [22]. This abnormal 
localization may be caused by the effect this mutation has in the fast 
component of α-syn’s axonal transport [20]. Another possibility, which we 
took in account in our study, is that some gain of toxicity of mutant α-syn 
is due to spurious binding to biomolecules, namely protein partners, which 
may sequester α-syn and hinder its normal axonal transport and subcellular 
localization at the synapses. 
In this work, we established a new Drosophila model for PD, based 
on the expression of EGFP-tagged versions of wild-type and A30P mutant 
α-syn in the photoreceptors, using the Gal4/UAS system. We observed 
mislocalization of α-syn A30P mutant in the Drosophila photoreceptors, 
comparing to the wild-type form. In order to clarify the molecular 
mechanisms responsible for the axonal transport and synaptic localization 




of α-syn, we performed proteomic analysis by co-IP and mass 
spectrometry identification of the specific protein interactors for α-syn 
wild-type and A30P mutant. Subsequently, we performed an RNAi genetic 
screen, using the identified protein interactors, aiming to discover possible 





2.3.1. The wild-type form of α-syn accumulates in the synaptic 
terminals of Drosophila photoreceptors 
Using the sGMR Gal4 driver, we induced the expression of the wild-
type version of α-syn in the Drosophila eye, generating a consistent 
phenotype where α-syn was found to be localized in the terminal portion of 
the photoreceptors’ axons (Fig. 2.2). This observation is consistent with 
the fact that α-syn is a neuronal protein highly enriched in the synaptic 
terminals of vertebrate’s nervous system.  
 
 
Figure 2.2. The wild-type version of α-syn accumulates in the terminal portion of 
Drosophila photoreceptor’s axons. Horizontal retinal cryosection, in which the 
photoreceptors were marked by anti-chaoptin. The triangles point to the layers 
where the photoreceptors’s axons project into the brain. The photoreceptors 1-6 
(R1-R6) project into the lamina, while the photoreceptors 7 (R7) and 8 (R8) 









2.3.2. The A30P mutant version of α-syn is mislocalized in the 
Drosophila photoreceptors 
The expression of α-syn A30P mutant form, under the control of the 
sGMR Gal4 driver, led to a strikingly different phenotype comparing to 
the one characterized for the wild-type form (Fig. 2.3). The A30P mutant 
version of α-syn lost the specific synaptic enrichment and was found 




Figure 2.3. The A30P mutant version of α-syn is mislocalized in the Drosophila 
photoreceptors. (A) The subcellular localization of the wild-type form of α-syn is 
mainly synaptic, accumulating in the axon terminals of photoreceptors. Genotype: 
sGMR-GAL4, UAS-α-synWT-EGFP. (B) The A30P mutant form of α-syn is 
detected throughout the cell bodies of the photoreceptors, losing its synaptic 






In order to ensure that the eye phenotypes observed were not a 
simple consequence of different levels of transgene expression in the two 
independent UAS lines, rendering different protein levels for the wild-type 
and A30P mutant versions of α-syn, we performed an immunoblot using 
cellular extracts from these two UAS lines (Fig. 2.4). We found that the 




Figure 2.4. The two independent UAS transgenic lines encoding for the wild-type 
and the A30P mutant versions of α-syn, show similar levels of transgene 
expression, at the protein level. Immunoblotting (anti-EGFP) of total protein 
extracts from flies expressing the transgenes (α-synWT-EGFP, α-synA30P-EGFP 
or EGFP), under the control of sGMR-Gal4 driver. Genotypes: (WT) Genotype: 
sGMR-GAL4, UAS-α-synWT-EGFP. (A30P) sGMR-GAL4, UAS-α-synA30P-








2.3.3. No differences were detected in the aggregation state of the wild-
type and the A30P mutant version of α-syn 
In order to explain the difference in phenotypes observed for the 
wild-type and mutant (A30P) forms of α-syn, in terms of α-syn’s sub-
cellular localization in the photoreceptors, we tried to characterize the state 
of α-syn aggregation in our PD model, using the conformational antibodies 
OC and A11 in dot blot analysis. The conformational antibodies A11 and 
OC recognize, respectively, generic epitopes of soluble oligomers and 
fibrils within amyloid proteins [23, 24]. The OC antibody is specific for 
the fibrillar state recognizing fibrils, being not reactive to prefibrillar 
oligomers or monomers, while A11 antibody is specific for the prefibrillar 
state, not recognizing the fibrillar state. In the dot blots analysis of fly head 
extracts, we could not observe affinity differences between the wild-type 
and the mutant A30P form of α-syn, for the conformational antibodies OC 
and A11 (Fig. 2.5). Furthermore, all samples, including controls without 
α-syn, reacted to the conformational antibodies, thus suggesting a high 
level of amyloidogenic proteins in the Drosophila brains. As expected, in 
our controls, α-syn aggregates made from purified α-syn bound both OC 
and A11. Therefore this method was not suitable to probe for the 







Figure 2.5. Characterization of the aggregation state of the wild-type and the A30P 
mutant form of α-syn by dot blot analysis, using the conformational antibodies OC 
and A11. No differences were detected in the aggregation state of these two 
versions of α-syn for both conformational antibodies tested, being both samples 
equally reactive (C and D). Samples from control genotypes (A and B) were also 
reactive to the antibodies. In the box, are indicated the genotypes and the type of 
aggregates (generated in vitro) tested, as well as the total protein quantities (µg) 
used in this assay. 
 
 
In another attempt to characterize the aggregation state of α-syn in 
our Drosophila model, we performed immunohistochemistry staining of 
retinal cryosections with Congo Red and Thioflavin S dyes, two major 
histological stains used to detect any form of amyloid. These dyes bind to 
the characteristic β-pleated sheet conformation of amyloid fibrils, not 
binding to non-fibrillar diffuse aggregates [25]. Once again, we could not 
find any difference concerning the aggregation state of the two versions α-
syn tested. We obtained the same staining profile for both genotypes tested 
separately for Congo Red and Thioflavin S (Fig. 2.6). 
 






Figure 2.6. Characterization of the aggregation state of the wild-type and the A30P 
mutant form of α-syn, using Congo Red and Thioflavin S. No difference was 
detected in the aggregation state of these two versions of α-syn, when tested by 
staining of retinal cryosections with Congo Red and Thioflavin S (A and B). DAPI 
indicates the position of cell nuclei in the retina. Genotypes – Syn WT: sGMR-







2.3.4. Identification of α-syn WT and A30P protein interactors by 
co-immunoprecipitation and mass spectrometry analysis 
As described in the section 2.3.3, the analysis of α-syn’s aggregation 
state in our model did not explain the striking difference in the phenotypes 
observed for the subcellular localization of the wild-type and the A30P 
mutant forms of α-syn in the Drosophila photoreceptors.  
Therefore, we decided to identify specific protein interactors for the 




Figure 2.7. The specific protein interactors for the wild-type and the A30P mutant 
forms of α-syn were identified by Co-IP and mass spectrometry. Protein extracts 
from each genotype were prepared and incubated with agarose beads coupled to 
anti-GFP (GFP Trap A), which specifically bind to the EGFP tagged versions of 
α-syn, promoting their pulldown. The efficiency of the pulldown was evaluated by 
immunoblot, using an antibody against the EGFP tag. The specific protein 
interactors were identified by mass spectrometry of the co-immunoprecipitated 
proteins, which were loaded in a Coomassie gel. 
  




The identification of the specific protein binding partners for the 
wild-type and A30P α-syn, especially the ones that uniquely interact with 
one of these versions (and not with the EGFP tag alone, which acts as a 
negative control), may constitute an opportunity for elaborating hypotheses 
of the biological processes (and plan further experiments that could 
corroborate these hypotheses) that may be behind the phenotypic 
differences observed in our model. By performing the Co-IP of our 
samples (SynWT-EGFP, SynA30P-EGFP and EGFP alone) and posterior 
identification of the protein interactors by mass spectrometry, we obtained 
a list containing a total of 2488 proteins. From these total number of 
proteins, we subtracted the ones that interacted with the GFP tag alone 
(1496), obtaining a list of 992 specific protein interactors. From the 992 
specific protein interactors, 304 were specific for the wild-type form, while 
303 were specific for the A30P mutant form of α-syn. The remaining 384 
proteins were identified as being protein partners of both versions of α-syn. 
Taking advantage of the DAVID software, we performed a gene 
ontology (GO) analysis which allowed us to identify the most enriched 
biological themes in our list of specific protein interactors, generating a 
general profile of the protein interactors for the two version of α-syn used 
in our study (Table 2.1). Interestingly, the results of this analysis were very 
consistent with the phenotypes observed in our model, since for the wild-
type form of α-syn the highest scores corresponded to GO terms mostly 
related to the synaptic vesicle transport, synapse and neurotransmission, 
while for the A30P mutant form of α-syn this enrichment was lost and the 
highest scores obtained corresponded to GO terms mostly related with 
mitochondria and ribosome. 
Importantly, some proteins identified as being specific interactors of α-




synaptobrevin, syntaxin, cysteine string protein and synapse protein 25 
[11, 26]. 
In order to validate and further characterize the interactome described 
in our study in the context of PD, the interaction of α-syn with the specific 
proteins identified by mass spectrometry should be validated by 
immunoblot analysis using specific antibodies for these proteins. We 
successfully validated the interaction of the wild-type version of α-syn 
with Ferritin 1 heavy chain homologue, one of the specific protein 
interactors identified by mass spectrometry (Fig. 2.8). 
 
 
Figure 2.8. The interaction between wild-type α-syn and Ferritin 1 heavy chain 
homologue (Fer1HCH) was demonstrated by Co-IP and immunoblot analysis. 
Immunoprecipitation of α-syn-EGFP with an antibody against the EGFP tag 
pulled down Fer1HCH from photoreceptors. Genotype: sGMR-GAL4, UAS-α-
synWT-EGFP 




Table 2.1. Gene ontology (GO) analysis of the specific interactors for the wild-
type and the A30P mutant forms of α-syn. The annotation clusters shown in the 






2.3.5. Tomosyn, Spaghetti Squash, and Synaptotagmin 4 are 
modulators α-syn axonal transport and subcellular localization 
Aiming to explain the differences observed in the axonal transport 
and subcellular localization for the wild-type and the A30P mutant forms 
of α-syn, we decided to perform a reverse RNAi screen to knock down the 
genes encoding specific protein interactors for these two versions of α-syn. 
For this genetic screen we used the RNAi lines from TRiP (Harvard 
Medical School) which were crossed with our line expressing the A30P 
mutant form of α-syn in the Drosophila eye. The aim was to identify 
modulator genes, which upon knock down, could promote the synaptic 
localization of A30P. From the 100 RNAi lines tested (Supplementary 
Table 2.1), we could identify 3 genes, enconding the proteins Tomosyn, 
Spaghetti Squash and Synaptotagmin 4, whose knock down promoted the 
synaptic localization of the A30P mutant form of α-syn (Figure 2.9).  
Tomosyn is a 120-130 kDa protein, firstly identified as a 
Syntaxin1a-binding protein [27], with a negative regulator effect on the 
SNARE-dependent exocytosis, resulting from the inhibition to the priming 
step involved in the fusion of the vesicles with the plasma membrane [28-
41]. Spaghetti Squash belongs to the group of myosin light chain proteins 
and is required for cytokinesis in Drosophila [42]. Synaptotagmin 4 is one 
of the members of the family of membrane-trafficking proteins, with the 
ability to bind calcium and to control neurotransmission by promoting the 
fusion of the vesicles containing neurotransmitters with plasma 
membranes [43]. Interestingly, the three candidate molecular modulators 
were closely related to neurotransmission and to the SNARE complex 
functioning. One may speculate that part of the toxicity of the A30P 
mutant version of α-syn could be caused by the abnormal interaction with 
other neuronal proteins, namely molecular players involved in the control 
of the neurotransmitters’ release into the synaptic cleft. 






Figure 2.9. Tomosyn, Spaghetti Squash and Synaptotagmin 4, were identified in a 
RNAi screen, as modulators of α-syn’s axonal transport in Drosophila 
photoreceptors. (A) The genetic screen consisted in performing the knocking-
down of the genes encoding the specific proteins identified by 
immunoprecipitation and mass spectrometry as specific interactors of the mutant 
A30P form of α-syn, in the genetic background of flies expressing this mutant 
form of α-syn in the photoreceptors.  (B, C, D) Tomosyn, Spaghetti Squash and 
Synaptotagmin 4 are 3 genes identified as being able to rescue the phenotype 
characterized for the wild-type form of α-syn (when genetically knocked down), 
thus being candidate modulator genes for the axonal transport and subcellular 
location of α-syn. The main biological functions of these genes (by UniProt) are 





In our study we used a newly established Drosophila model for PD, 
expressing the wild-type and the mutant A30P versions of α-syn fused 
with EGFP.  
Taking advantage of the Gal4/UAS system, we induced the 
expression of these proteins in the eye, using the sGMRGal4 driver. We 
observed a consistent phenotype with our model for the subcellular 
localization of the two versions of α-syn in the photoreceptors: the wild-
type version was mainly detected in the photoreceptors’ synapses, while 
the mutant A30P form was detected throughout the whole photoreceptors 
cytoplasm. 
The synaptic enrichment of the wild-type version of α-syn in our 
model is consistent with the normal localization of this protein in the 
vertebrate nervous system. We believe this observation may constitute a 
good indication that Drosophila nervous system and, in this particular 
case, our PD model based on the expression of α-syn in the photoreceptors, 
may be a useful tool to study α-syn’s biology at the molecular and cellular 
level and the relevance of this protein in the neurodegenerative context of 
PD. 
 The loss of the normal synaptic enrichment by the A30P mutant 
form of α-syn may be associated with the deleterious effect of this mutant 
form of the protein, responsible for a familial form of PD. The negative 
effects of this mislocalization could be caused by the loss of function of 
α-syn in the synaptic processes and/or by gain of toxicity by increasing the 
propensity of this protein to interact, co-aggregate and accumulate with 
other neuronal proteins in the typical protein aggregates, commonly known 
as Lewy Bodies, found in post-mortem analysis of PD patients’ brains. It is 
still unclear if the mislocalization of α-syn is an early cause or a 
consequence of the neurodegenerative events occurring in the context of 




PD and more studies, carefully designed with proper controls, are needed 
to clarify this issue. 
In order to characterize the aggregation state of the two versions of 
α-syn (wild-type and A30P) used in our study, we performed two different 
experiments. In one of these experiments, we used the conformational 
antibodies OC and A11 in dot blot analysis, in the other we used the 
Congo Red and Thioflavin S dies for immunohistochemistry of retinal 
cryosections. These experiments did not contribute for the explanation of 
the phenotypic differences observed in our model, since the results 
obtained were similar for all the samples tested, with no differences being 
detected between the lines expressing the wild-type or the A30P mutant 
version of α-syn. The differential phenotypes found were not the simple 
consequence of different states and/or levels of aggregation of the two 
versions of α-syn tested. 
A simple and plausible explanation for the phenotype observed in 
our model for the A30P mutant form of α-syn is the loss of ability to bind 
to the vesicles moved by the fast component of axonal transport, being the 
transport of this mutant version of α-syn to the synapses less efficient, 
when compared to the wild-type version, and consequently a bigger 
quantity of this mutant version of α-syn can be detected throughout the 
cytoplasm of the photoreceptors. 
An alternative hypothesis that we took into account in our study, is a 
change in the affinity and propensity to interact with other biomolecules, 
namely the neuronal protein partners, by the A30P mutant form of α-syn. 
The experimental approach we chose to test this last hypothesis consisted 
in the identification of the specific protein partners for the wild-type and 
A30P mutant versions of α-syn, by Co-IP and mass spectrometry. We 
could identify 304 protein partners specific for the wild-type form of α-syn 




found for each of these versions of α-syn were quite consistent with the 
phenotypes observed. For the wild-type version of α-syn, detected as being 
highly enriched in the synaptic terminals of the photoreceptors, the protein 
partners with highest scores were related to neurotransmission at the 
synapses, while for the A30P mutant form the majority of protein partners 
were associated to mitochondria or ribosome. The protein interactors 
selected in our study are indicated in Supplementary Table 2.1 
The identification of the specific protein interactors for the A30P 
mutant form of α-syn, allowed us to perform a reverse genetic RNAi 
screen aiming to identify protein modulators that could reverse or 
ameliorate de subcellular mislocalization of this α-syn version. From the 
total number of 303 specific partners identified, we tested 100, the ones 
having a correspondent RNAi line available at TRiP stock center (Harvard 
Medical School) (Supplementary Table 2.2). From these 100 genes tested, 
we found 3 (Tomosyn, Spaghetti Squash and Synaptotagmin 4) that could 
rescue/ameliorate the phenotype, increasing the amount of α-syn A30P at 
the synapse. 
  




2.5. Material and Methods 
Drosophila stocks 
We generated two different UAS-α-Syn-EGFP lines, one encoding a 
wild-type version of α-syn (UAS-α-synWT-EGFP) and the other encoding 
a familial mutant version of α-syn (UAS-α-synA30P-EGFP). To generate 
and subclone these constructs from the original plasmids, we fused α-syn 
cDNAs with EGFP and cloned into pUAST using the BglII and Acc65I 
restriction sites. The transgenic flies were generated by BestGene, USA. 
Four different drivers were obtained from the Bloomington Stock Center 
(Indiana University, Bloomington, IN, USA): nSyb-GAL4 (active in the 
entire nervous system, under the control of the Synaptobrevin promoter), 
TH-GAL4 (active in dopaminergic neurons, under the control of the 
tyrosine hydroxylase promoter), GMR-GAL4 (active in the eye, under the 
control of the glass multiple reporter) and Rh1-GAL4 (active in the 
photoreceptors R1–R6, under the control of the rhodopsin1 promoter).  
The RNAi lines were obtained from TRiP at Harvard Medical 
School (NIH/NIGMS R01-GM084947). Drosophila stocks were 
maintained at 25°C on standard cornmeal media in an incubator with a 
12 h light/dark cycle. 
 
Immunohistochemistry and microscopy 
Retinal cryosections of adult flies were done for confocal 
microscopy imaging. Briefly, adult heads were embedded in OCT 
(Optimal Cutting Temperature, Tissue-Tek) and frozen at -20ºC. 
Subsequently, 10 µm sections were cut in a cryostat (Microm HM 550). 
The samples were fixed during 20 min in PBS 1X + formaldehyde 4%. 
Finally, we proceeded  with the immunostaining of the cryosections, as 




by incubation for 24 h at 4°C, in a humid Tupperware box, with mouse 
24B10 anti-chaoptin antibody (Developmental Studies Hybridoma Bank – 
IA, USA) diluted 1:150 in PBST (1× PBS + 0.3% Triton X-100) 
containing 5% (v/v) normal goat serum. Three 10-min washes with PBST 
were done before incubation with a secondary anti-mouse Cy3 (Jackson 
ImmunoResearch), also diluted in PBST-containing 5% (v/v) normal goat 
serum. The retinal cryosections were analyzed and images were collected 
using a LSM 710 Meta Zeiss confocal microscope. Images were acquired 
with a resolution of 1024 × 1024, with a slice thickness of 1 µm and a line-
average of 4. Z-projections were generated using ImageJ and the images 
were processed using Adobe Photoshop. For the Congo Red and 
Thioflavin S (Sigma) stainings we performed the protocol previously 
described, with small adaptions [45]. 
 
Dot blotting using amyloid conformational antibodies 
10µl of of each sample was dotted in triplicates onto PVDF 
membranes and probed with a 1:500 dilution of the anti-amyloid oligomer 
A11 antibody (AB9234 Merck Millipore) and 1:1000 for the anti-amyloid 
fibrils OC antibody (AB2286 Merck Millipore) according to manufacturer 
instructions. Dots were visualized using an IgG HRP conjugate secondary 
antibody with a chemiluminescence detection system (GE Healthcare). 
Images were recorded and analyzed using the quantity one analysis 










Flies were transferred to 50-ml tubes, frozen in liquid nitrogen and 
immediately decapitated by vigorous vortexing. Isolated heads were 
collected to 1.5-ml tubes and maintained in dry ice. Proteins were 
extracted in lysis buffer supplemented with Complete Protease Inhibitor 
Cocktail tablets from Roche (Basel, Switzerland). Total protein was 
quantified using the DC Protein Assay, from Bio-Rad (CA, USA). In the 
immunoprecipitation experiments, α-syn-EGFP, α-synA30P-EGFP and 
EGFP alone were pulled down from 2 mg of total protein extract, using 
GFP-Trap_A beads, following manufacturer’s instructions (Chromotek, 
Munich, Germany). The pull-down of the proteins of interest was analyzed 
by immunoblotting using anti-GFP (3H9) antibody from Chromotek, 
diluted 1:1000 in PBS. Input lane corresponds to 30 µg of total protein 
extract and co-IP lane corresponds to one-fifth of the immunoprecipitated 
material. 
 
Mass spectrometry analysis 
After protein separation on a SDS–PAGE (4-12% NuPAGE Bis-Tris 
Gel, Invitrogen), the entire lanes of the Coomassie blue-stained gel were 
cut into 23 slices. All slices were reduced with 10 mM DTT for 55 min at 
56°C, alkylated with 55 mM IAA for 20 min at 26°C and digested with 
modified trypsin (Serva) overnight at 37°C. Tryptic peptides were injected 
into a C18 pre-column (25 mm, 360 μm o.d., 150 μm i.d., Reprosil-Pur 
120 Å, 5 μm, C18-AQ, Dr Maisch GmbH) at a flow rate of 10 μl/min. 
Bound peptides were eluted and separated on a C18 capillary column (12 
cm, 360 μm o.d., 75 μm i.d., Reprosil-Pur 120 Å, 3 μm, C18-AQ, Dr 
Maisch GmbH) at a flow rate of 300 nl/min, with a gradient from 5 to 36% 
ACN in 0.1% formic acid for 50 min using an Agilent 1100 nano-flow LC 




mass spectrometer (Thermo Fisher). The mass spectrometer was operated 
in the data-dependent mode to automatically switch between MS and 
MS/MS acquisition. Survey MS spectra were acquired in the Orbitrap (m/z 
350–1600) with the resolution set to 30,000 at m/z 400 and automatic gain 
control target at 5 × 10E5 ions. The fifteen most intense ions were 
sequentially isolated for CID MS/MS fragmentation and detection in the 
linear ion trap. Ions with single and unrecognized charge states were 
excluded. Raw data was analyzed with Mascot search engine for peptide 
and protein identifications. The mass spectrometry analysis was performed 
in the Bioanalytic mass spectrometry facility at the Max Planck Institute 
for Biophysical chemistry, Goettingen. 
Proteomic data analysis 
We used Ingenuity Pathways Analysis (Ingenuity Systems®, 
www.ingenuity.com, IPA) software to integrate the identified proteins into 
signaling pathways with biological meaning. Functional analysis identified 
the most significant molecular and cellular functions and/or disorders to 
each dataset. For the identification of the enriched biological themes and 
the Gene Ontology terms, we used DAVID (Database for Annotation, 














Supplementary Table 2.1. Specific protein interactors identified by co-IP 
and mass spectrometry selected in our study. 
    Nº Unique Peptides 
Protein CG UniProt MW SynWT SynA30P GFP 
1-cys peroxiredoxin 
DPx-2540-1 CG12405 Q9GPQ1 
25 
kDa 3 4 0 
1-cys peroxiredoxin 
DPx-6005 CG3083 Q9GPQ2 
25 
kDa 2 0 0 




CG30420 Q9W0Z5 93 kDa 5 2 0 
AKAP550 CG6775 Q9W4E2 393 kDa 2 4 0 
annexin B11, isoform 
A CG9968 Q9VXG4 
36 
kDa 4 0 0 
Arc2 CG13941 Q7JV70 23 kDa 4 0 0 
Arpc3A, isoform C CG4560 Q9VF28 20 kDa 4 2 0 
baldspot, isoform A CG3971 Q9VV87 37 kDa 0 2 0 
basigin, isoform A CG31605 Q8IPG9 29 kDa 0 2 0 
beta subunit of type II 
geranylgeranyl 
transferase 
CG18627 Q9XZ68 39 kDa 2 2 0 
brahma protein CG5942 P25439 185 kDa 2 6 0 
bride of sevenless CG8285 P22815 100 kDa 0 3 0 
brown protein CG17632 P12428 76 kDa 0 2 0 
bruce CG6303 Q9VH01 539 kDa 3 3 0 
bunched, isoform F CG42281 Q24523 113 kDa 2 0 0 
c12.2 CG12149 Q9W347 156 kDa 7 4 0 
cactus zygotic protein CG5848 Q03017 52 kDa 3 2 0 
calmodulin, isoform 
A CG8472 P62152 
17 
kDa 0 4 0 
calmodulin-binding 
protein CG18345 P48994 
128 
kDa 9 13 0 




Ced-12 CG5336 Q9VKB2 83 kDa 7 4 0 
CG10075 CG10075 Q9VRZ7 29 kDa 3 2 0 
CG10253, isoform A CG10253 Q9V778 71 kDa 3 2 0 
CG10362 CG10362 Q9VYR9 115 kDa 0 3 0 
CG10417, isoform A CG10417 Q7K4Q5 72 kDa 0 3 0 
CG10562 CG10562 Q961Q8 46 kDa 2 0 0 
CG10915 CG10915 Q8SX68 65 kDa 3 3 0 
CG10973, isoform B CG10973 Q95RI2 34 kDa 3 2 0 
CG10990, isoform A CG10990 Q9VY91 56 kDa 0 2 0 
CG1104, isoform A CG1104 Q9VI55 87 kDa 5 3 0 
CG11055, isoform B CG11055 Q7JR83 97 kDa 4 0 0 
CG11092 CG11092 Q9XZ06 94 kDa 4 3 0 
CG1134 CG1134 Q9VZJ9 38 kDa 0 3 0 
CG11679 CG11679 Q9VXQ8 48 kDa 4 2 0 
CG11875 CG11875 Q9VBU8 35 kDa 2 0 0 
CG11943, isoform B CG11943 Q8IQV9 235 kDa 8 6 0 
CG12082 CG12082 Q9VZU7 92 kDa 3 3 0 
CG12121 CG12121 Q9W366 84 kDa 2 2 0 
CG12355, isoform B CG12355 A8JNT1 23 kDa 2 0 0 
CG12547 CG12547 Q9W5T4 80 kDa 3 0 0 
CG13365 CG13365 Q9W5E7 14 kDa 0 2 0 
CG13506 CG13506 Q9W259 57 kDa 7 5 0 
CG14184, isoform A CG14184 Q9VW73 21 kDa 4 0 0 
CG14591, isoform A CG14591 Q7JRB2 38 kDa 2 4 0 
CG14786 CG14786 Q9W592 120 kDa 4 7 0 
CG15118, isoform E CG15118 A8DYI9 71 kDa 2 4 0 




CG15661, isoform B CG15661 Q9W2J3 61 kDa 7 0 0 
CG17493 CG17493 Q8SXJ8 32 kDa 2 2 0 
CG17514, isoform A CG17514 Q7PLL6 294 kDa 2 6 0 
CG17528, isoform D CG17528 Q7PLI7 83 kDa 0 4 0 
CG17839, isoform B CG17839 Q7KUK9 179 kDa 3 2 0 
CG18259 CG18259 Q9VWQ6 53 kDa 3 0 0 
CG1909, isoform A CG1909 Q7K4Y8 67 kDa 4 4 0 
CG2658, isoform A CG2658 Q9W4W8 90 kDa 3 3 0 
CG30291 CG30291 Q95SK3 58 kDa 3 2 0 
CG3036 CG3036 Q9VR44 54 kDa 2 0 0 
CG31436 CG31436 Q8IMT3 50 kDa 2 0 0 
CG3164, isoform B CG3164 Q9VPJ9 78 kDa 6 7 0 
CG31760, isoform B CG31760 Q9VKA4 98 kDa 5 4 0 
CG32226 CG32226 Q9VWB0 149 kDa 4 2 0 
CG3226 CG3226 Q9W3Y3 26 kDa 3 3 0 
CG32649 CG32649 Q9VYI6 74 kDa 4 4 0 
CG32699, isoform B CG32699 Q0KHU5 60 kDa 3 0 0 
CG34132 CG34132 Q0E8V7 10 kDa 0 3 0 
CG34228 CG34228 Q6IGN6 10 kDa 2 2 0 
CG34306 CG34306 A8JQT5 406 kDa 3 0 0 
CG34310, isoform A CG34310 A8DYW4 9 kDa 2 2 0 
CG3436, isoform A CG3436 Q9VPL0 39 kDa 2 0 0 
CG34417, isoform H CG34417 A8JV00 558 kDa 6 2 0 
CG3532 CG3532 Q9VGE4 130 kDa 2 5 0 
CG40042, isoform A CG40042 Q8MRW1 22 kDa 2 3 0 




CG4038 CG4038 Q7KVQ0 23 kDa 4 0 0 
CG40451 CG40451 Q7PLT4 18 kDa 4 4 0 
CG42354, isoform A CG42354 Q8IR21 57 kDa 0 3 0 
CG4289 CG4289 Q9VPB8 31 kDa 3 2 0 
CG4666 CG4666 Q9W440 23 kDa 4 4 0 
CG4688 CG4688 Q7JYX0 27 kDa 0 3 0 
CG5112 CG5112 Q9VBQ5 58 kDa 5 5 0 
CG5154 protein CG5154 E1UIB8 50 kDa 4 0 0 
CG5508, isoform A CG5508 Q9Y137 95 kDa 4 4 0 
CG6123 CG6123 Q9VWW2 64 kDa 6 2 0 
CG6364, isoform B CG6364 B7Z0P8 34 kDa 3 4 0 
CG6406, isoform B CG6406 Q7K1C5 60 kDa 2 2 0 
CG6523 CG6523 Q9VJZ6 24 kDa 4 5 0 
CG7135 CG7135 Q9VWY5 49 kDa 3 2 0 
CG7215, isoform A CG7215 Q9VEC8 15 kDa 0 3 0 
CG7261 CG7261 Q9VQ78 135 kDa 3 2 0 
CG7378, isoform B CG7378 A8JUQ2 26 kDa 3 2 0 
CG7770 CG7770 Q9VW56 14 kDa 0 2 0 
CG7772 CG7772 Q9VX02 18 kDa 2 2 0 
CG7900 CG7900 Q9VHV9 59 kDa 5 0 0 
CG7956, isoform B CG7956 Q59DV6 126 kDa 5 6 0 
CG8031 CG8031 Q9VG04 33 kDa 2 3 0 
CG8176, isoform C CG8176 Q6AWD5 130 kDa 4 4 0 
CG8298, isoform A CG8298 Q7JY99 66 kDa 0 4 0 
CG8329 CG8329 Q9VT23 28 kDa 8 4 0 
CG8858 CG8858 Q9V677 212 kDa 0 9 0 




CG9009, isoform A CG9009 Q9VXZ8 66 kDa 3 3 0 
CG9027, isoform D CG9027 Q0E9C3 23 kDa 2 0 0 
CG9339, isoform A CG9339 Q9VIH7 67 kDa 3 0 0 
cGMP-dependent 
protein kinase CG10033 Q03043 
121 
kDa 4 2 0 
CHKov2 CG10675 Q9VBS0 48 kDa 2 0 0 
complexin, isoform A CG32490 Q8IPM8 16 kDa 2 0 0 
CP60 CG1825 Q24147 48 kDa 0 3 0 
Cullin-3, isoform C CG11861 Q9V475 90 kDa 2 0 0 
DCAPL1 CG18408 Q966V1 268 kDa 3 2 0 
down syndrome cell 
adhesion molecule, 
isoform AK 
CG17800 Q0E9K5 224 kDa 0 2 0 
Dsrc41 CG7873 Q9V9J3 59 kDa 8 7 0 
D-stat protein short 
form CG4257 Q24151 
86 
kDa 3 0 0 
dystrophin, isoform 
H CG34157 Q9VDW6 
410 
kDa 2 4 0 
fermitin 1, isoform A CG14991 Q9VZI3 80 kDa 2 5 0 
ferritin 1 heavy chain 
homologue, isoform 
A 
CG2216 Q7KRU8 23 kDa 5 4 0 
focal contact protein 
paxillin CG31794 Q9GSE0 
62 
kDa 7 0 0 
G protein alpha49B, 
isoform H CG17759 P23625 
42 
kDa 4 4 0 
G protein alphai 
subunit 65A CG10060 P20353 
41 
kDa 0 4 0 
G protein gamma 1, 
isoform C CG8261 P38040 
8 
kDa 4 3 0 
G protein-coupled 
receptor kinase 2 CG17998 P32866 
81 
kDa 0 3 0 
gamma-syntrophin-
like protein SYN2 CG4905 Q9GT68 
53 
kDa 0 2 0 
glutamate-gated 
chloride channel CG7535 Q94900 
52 





CG33546 Q8INS9 27 kDa 3 3 0 




histone deacetylase 6 
isoform A CG6170 Q86NK9 
125 
kDa 0 6 0 
hook CG10473 Q9VJ12 77 kDa 4 3 0 
hook-like, isoform A CG10473 Q9VJ12 84 kDa 4 2 0 
junctophilin CG4405 Q966S5 116 kDa 3 2 0 
kismet, isoform A CG3696 Q9VPL9 574 kDa 0 2 0 
krueppel target at 
95D, isoform A CG5405 Q9VCE7 
125 
kDa 5 2 0 
kugelkern, isoform A CG5175 Q8SX89 60 kDa 2 0 0 
laminin B2 chain CG3322 P15215 182 kDa 7 0 0 
lin19 protein CG1877 Q24311 89 kDa 2 2 0 
longitudinals lacking, 
isoform D CG12052 Q7KQZ4 
79 
kDa 2 2 0 
MAP kinase activated 
protein-kinase-2, 
isoform B 
CG3086 P49071 41 kDa 0 3 0 
MAP kinase kinase 4, 
isoform A CG9738 O61444 
48 
kDa 3 2 0 
Mi-2, isoform A CG8103 O97159 224 kDa 5 6 0 
microtubule 
associated protein CG5000 Q9U5W6 
227 
kDa 4 8 0 
mitoferrin CG4963 Q9VAY3 42 kDa 0 3 0 
Myb-interacting 
protein 40 CG15119 Q7K159 
30 
kDa 4 4 0 
myosin heavy chain-
like, isoform G CG31045 Q0KI67 
242 
kDa 5 11 0 
neural lazarillo CG33126 Q8SXR1 24 kDa 6 4 0 
nitric oxide synthase CG6713 Q27571 152 kDa 5 5 0 
no mitochondrial 
derivative CG5395 Q9VL02 
42 
kDa 3 4 0 
p115 CG1422 Q9W3N6 92 kDa 2 6 0 




CG9181 Q9W0G1 62 kDa 3 2 0 
pyruvate 
dehydrogenase 
kinase, isoform B 
CG8808 A8DY78 48 kDa 0 5 0 





protein, isoform A CG6606 Q9VWS3 
92 
kDa 5 0 0 
Rab35, isoform A CG9575 Q9W5X0 23 kDa 7 5 0 
rab3-GEF, isoform A CG5627 A8JUX2 225 kDa 9 12 0 
rho-like CG9366 Q24192 22 kDa 7 5 0 
ric8a CG15797 Q9W358 66 kDa 4 3 0 
roadblock CG10751 Q7KMS3 11 kDa 3 0 0 
Roe1 CG6155 P48604 24 kDa 4 3 0 
sec10 CG6159 Q9XTM1 82 kDa 0 4 0 
slowpoke binding 
protein, isoform A CG6772 Q8IPH9 
58 
kDa 2 2 0 
SP2637, isoform C CG5473 Q7KIS4 35 kDa 0 5 0 
spaghetti squash CG3595 P40423 20 kDa 7 2 0 
spenito, isoform B CG2910 Q7KMJ6 89 kDa 7 0 0 
synaptojanin, isoform 
B CG6562 Q5U0V7 
135 
kDa 2 2 0 
synaptotagmin 4 CG10047 Q9U6P7 52 kDa 3 0 0 
syndecan, isoform A CG10497 P49415 42 kDa 4 0 0 
syntaxin 8 CG4109 Q9VV76 26 kDa 2 2 0 
target of rapamycin CG5092 Q9VK45 281 kDa 2 3 0 
tho2, isoform A CG31671 Q9VQ76 189 kDa 0 3 0 
tomosyn, isoform C CG17762 Q9VYK6 158 kDa 3 5 0 
translocation protein 
1, isoform A CG4758 Q9VL50 
47 
kDa 4 3 0 
transport and golgi 
organization 5, 
isoform A 
CG32675 Q9W2S1 58 kDa 5 5 0 
Trs23 CG9298 Q9VLI9 25 kDa 2 2 0 
Ucp4A, isoform A CG6492 Q9VX14 37 kDa 2 4 0 
vacuolar protein 
sorting 45 CG8228 Q9VHB5 
65 





Supplementary Table 2.2. RNAi lines from TRiP (Harvard Medical 
School) tested in the reverse genetic screen for modulators of α-syn sub-
cellular localization. 
Protein name CG Bloomington TRiP 
1-cys peroxiredoxin DPx-2540-1 CG12405 32497 HMS00500 
A kinase anchor protein 200, isoform D CG13388 28532 HM05018 
Ac3, isoform A CG1506 28626 JF03041 
acetylcholine esterase, isoform A CG17907 25958 JF01978 
activating transcription factor-2, 
isoform A CG30420 26210 JF02108 
annexin B11, isoform A CG9968 38311 HMS01775 
Arpc3A, isoform C CG4560 27044 JF02370 
bendless, isoform A CG18319 28721 JF03148 
beta subunit of type II geranylgeranyl 
transferase CG18627 34902 HMS01247 
beta-coatomer protein CG6223 33741 HMS01079 
brahma protein CG5942 34520 HMS00050 
bruchpilot, isoform H CG42344 25891 JF01932 
bubblegum CG4501 28639 JF03054 
bunched, isoform F CG42281 28322 JF02954 
cactus zygotic protein CG5848 34775 HMS00084 
calcium activated protein for secretion, 
isoform B CG33653 31984 JF03418 
Calcium/calmodulin-dependent protein 
kinase, isoform B CG6703 32857 HMS00644 
calcium-independent phospholipase A2 
VIA, isoform A CG6718 36129 HMS01544 
calmodulin, isoform A CG8472 34609 HMS01318 
calmodulin-binding protein CG18345 26722 JF02264 
carnation, isoform A CG12230 34007 HMS00972 




Cdk5 gene CG8203 27517 JF02667 
Ced-12 CG5336 28556 HM05042 
CG10132 CG10132 31992 JF03427 
CG10253, isoform A CG10253 34350 HMS01339 
CG10417, isoform A CG10417 39051 HMS01971 
CG10915 CG10915 34879 HMS00199 
CG11092 CG11092 33908 HMS00850 
CG12082 CG12082 31886 JF02163 
CG17514, isoform A CG17514 34355 HMS01344 
CG17528, isoform D CG17528 26292 JF02061 
CG18259 CG18259 34081 HMS01089 
CG1909, isoform A CG1909 28024 JF02858 
CG31103 CG31103 28359 JF02995 
CG32226 CG32226 34370 HMS01359 
CG3226 CG3226 32875 HMS00662 
CG4038 CG4038 34013 HMS00979 
CG6364, isoform B CG6364 35351 GL00263 
CG8298, isoform A CG8298 34524 HMS00813 
CG8858 CG8858 34975 HMS01128 
complexin, isoform A CG32490 42017 HMS02442 
connector of kinase to AP-1, isoform A CG7392 34522 HMS00081 
CP60 CG1825 32458 HMS00457 
Cullin-3, isoform C CG11861 36684 HMS01572 
DCAPL1 CG18408 36663 HMS01551 
dj-1beta CG1349 38999 HMS01915 
D-stat protein short form CG4257 33637 HMS00035 




focal contact protein paxillin CG31794 28695 JF03111 
G protein alpha49B, isoform H CG17759 36775 JF02390 
G protein alphai subunit 65A CG10060 34924 HMS01273 
G protein gamma 1, isoform C CG8261 34372 HMS01361 
G protein-coupled receptor kinase 2 CG17998 34843 HMS00161 
gamma-syntrophin-like protein SYN2 CG4905 28363 JF02999 
GST-containing FLYWCH zinc-finger 
protein, isoform D CG33546 32399 HMS00394 
highwire CG32592 28031 JF02866 
histone deacetylase 6 isoform A CG6170 34072 HMS0007 
Hsp70/Hsp90 organizing protein 
homolog CG2720 32979 HMS00779 
kinesin heavy chain CG7765 35770 HMS01519 
kinesin light chain CG5433 33934 HMS00883 
kismet, isoform A CG3696 34908 HMS01254 
Klp10A, isoform A CG1453 33963 HMS00920 
kugelkern, isoform A CG5175 28750 JF03178 
laminin A chain CG10236 28071 JF02908 
lin19 protein CG1877 29520 HM05197 
longitudinals lacking, isoform D CG12052 26714 JF02254 
megator CG8274 32941 HMS00735 
Mi-2, isoform A CG8103 33419 HMS00301 
microtubule associated protein CG5000 38990 HMS01906 
microtubule-associated protein CG1483 32939 HMS00733 
mitoferrin CG4963 34038 HMS01013 
Myb-interacting protein 40 CG15119 32834 HMS00524 
nitric oxide synthase CG6713 28792 JF03220 
Numb-associated kinase, isoform A CG10637 38326 HMS01793 




Phosphatidylinositol 4-kinase III alpha CG10260 38242 HMS01686 
presenilin, isoform A CG18803 38374 HMS01843 
protein tyrosine phosphatase 61F, 
isoform A CG9181 32426 HMS00421 
pyruvate dehydrogenase kinase, 
isoform B CG8808 28635 JF03050 
Rab11 interacting protein, isoform A CG6606 38325 HMS01792 
Rab35, isoform A CG9575 28342 JF02978 
rab3-GEF, isoform A CG5627 28954 HM05165 
Rab-protein 4, isoform B CG4921 33757 HMS01100 
rho-like CG9366 33723 HMS00605 
ric8a CG15797 28910 HM05121 
roadblock CG10751 31977 JF03411 
sec10 CG6159 27483 JF02633 
slowpoke binding protein, isoform A CG6772 27492 JF02642 
SP2637, isoform C CG5473 37522 HMS01664 
spaghetti squash CG3595 32439 HMS00437 
synaptojanin, isoform B CG6562 34378 HMS01368 
synaptotagmin 4 CG10047 39016 HMS01934 
syntaxin 8 CG4109 26013 JF02038 
target of rapamycin CG5092 33951 HMS00904 
tho2, isoform A CG31671 28537 HM05023 
tomosyn, isoform C CG17762 31980 JF03414 
Transcription elongation factor SPT5 CG7626 34837 HMS00153 
transportin, isoform A CG7398 CG7398 27546 JF02697 
Trs23 CG9298 38303 HMS01765 
vacuolar protein sorting 45 CG8228 38944 HMS01858 
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Huntington’s disease (HD) is an autosomal dominant neurodegenerative 
disorder caused by a mutation in the first exon of the IT-15 gene. This 
mutation encodes for an abnormally elongated polyglutamine (polyQ) 
amino acid sequence within the N-terminal region of huntingtin protein 
(Htt), leading to conformational changes of the protein, which dramatically 
increase its propensity to misfold and aggregate. N-terminal Htt fragments 
harboring the expanded polyQ tract are directly involved in HD 
pathogenesis. Our model for HD is based on the overexpression of an 
N-terminal truncated form of mutant human Htt, encoded by Htt exon 1 
(Httex1). Among the first 17 amino acid residues in the N-terminal (NT17) 
domain of Htt protein there are three that are susceptible to be post-
translationally modified by the action of kinases and phosphatases: 
threonine 3 (T3), serine 13 (S13) and serine 16 (S16). We analyzed the 
relative contribution of the phosphorylation state of each one of these 
amino acid residues to Httex1 oligomerization, aggregation and toxicity in 
mammalian cells and Drosophila. Single mutations mimicking the 
phosphorylation state of mutant Htt (phosphomimic mutants) at any of the 
three residues completely abolished Htt aggregation in cultured cells but 
enhanced aggregation in Drosophila. Biochemical inhibition or genetic 
knockdown of specific protein phosphatases also modulated Htt 
aggregation and toxicity. Our results indicate that single phosphorylation 
events in Httex1 are sufficient to modulate Htt aggregation and toxicity 
depending on the biological context. These findings suggest that 
modulation of Httex1 phosphorylation at specific sites might be a target for 






Huntington’s disease (HD) is a polyQ disease pathology caused by a 
mutation in the first exon of the IT-15 gene, which encodes for an 
expanded polyQ tract (with more than 36 glutamines) in the huntingtin 
protein (Htt), as previously explained in chapter I. 
N-terminal Htt fragments harboring the polyQ tract are directly 
involved in HD pathogenesis [1-6]. Neuronal aggregates enriched in this 
truncated forms of mutant Htt constitute an HD hallmark observed both in 
mouse models and in post-mortem analysis of patients’ brains [7]. Htt 
contains several proteolytic cleavage sites for different proteases, namely 
from the caspase family [8]. The cleavage of mutant Htt at the position 586 
by caspase-6 constitutes a prerequisite for neuronal dysfunction and death 
in HD [9]. For this reason, caspase-6 is currently considered one of the 
most attractive therapeutic targets for HD [10]. The relevance of Htt 
cleavage for HD is consistent with the fact that expression of the truncated 
protein containing Htt exon 1 is enough to produce HD in animal models 
[1, 5-7, 9].  
Our collaborators (Outeiro and Herrera) have recently developed a 
system for the simultaneous visualization of oligomeric species and 
inclusion bodies in living cells [11, 12] (Fig. 3.1). In this system, based on 
the Bimolecular Fluorescence Complementation (BiFC) assay, wild type 
(19Q) or disease-causing (97Q) Httex1 (the truncated form of Htt encoded 
by exon 1) are fused to two non-fluorescent halves of Venus, a bright 
yellow variant of the Green fluorescent protein. When Htt fragments 
dimerize, the Venus halves are brought together and reconstitute the 
functional fluorophore. Fluorescence is therefore proportional to the extent 
of Httex1 dimerization/oligomerization. Mutant versions of BiFC 
constructs were made for each of the phosphorylatable residues in NT17, 
changing these amino acids to either alanine (phosphoresistant) or to 




aspartic acid (phosphomimic). Importantly, these phosphomutants behave 
like phosphorylated peptides in terms of their aggregation in vitro [17]. 
 
Figure 3.1. Schematic representation of the BiFC cellular model used for the 
visualization of Htt oligomerization and aggregation in living mammalian cells. 
(A) Httex1 is fused to two non-fluorescent halves of the Venus fluorescent 
protein. When Htt dimerizes, the Venus halves are brought together, reconstituting 
the functional fluorophore and emitting fluorescence. (B) Using this BiFC system 
the monomeric species do not show fluorescence; dimers and oligomers show a 
homogeneously distributed fluorescence in the subcellular compartment where 
they are formed; large aggregates are observed as bright fluorescent regions, 
“scavenging” the fluorescence from the rest of the cell. Scale bar, 20 µm. Adapted 
from [13]. 
 
Our Drosophila model for HD is also based on the transgenic 
expression of the N-terminal truncated form of mutant human Httex1, 
which is constituted by three domains: the first 17 amino acids at the 







Figure 3.2. Schematic representation of the exon-1 truncated form of mutant Htt 
(Httex1) generated in our study. Httex1 is constituted by 3 domains: the first 17 
amino acids at the N-terminal domain (NT17), the polyQ tract and the proline-rich 
region (PRR). The amino acid sequence of NT17 is shown and its 
phosphorylatable sites (P) are indicated in yellow. The Phosphomutations 
generated in our study for the residues T3, S13 and S16 are also indicated. In the 
phosphomimetic mutants these residues were substituted for aspartate (D) while in 
the phosphoresistant mutants the substitutions were for an alanine (A). The 
fluorescent protein tag mCherry was fused to the C-terminal portion of Httex1. 
 
We generated an Httex1 construct containing an expanded polyQ 
tract of 97 glutamines and fused to the mCherry fluorescent tag in the c-
terminal domain (97QHttex1-mCherry). A wild-type form of this 
construct, with a polyQ tract containing 19 glutamines 
(19QHttex1-mCherry), was also generated. 
Post-translational modifications (PTMs) have a critical role in the 
structure and function of proteins and several studies have suggested a 
major role for PTMs in HD pathogenesis (reviewed in [14]). Htt contains 
several residues susceptible to be post-translationally modified in the 
NT17 domain. The most common PTMs in the NT17 are phosphorylation, 
ubiquitination, SUMOylation and acetylation [15]. Concerning the 
phosphorylation in NT17, there are 3 amino acid residues susceptible to 
the action of kinases and phosphatases: threonine 3 (T3), serine 13 (S13) 
and serine 16 (S16). Phosphorylation is one of the most prevalent and 
studied PTM in the context of HD, and previous studies have shown that 




phosphorylation of mutant Htt has a protective role in HD, affecting the 
aggregation and toxicity levels of this protein [16-19]. Presently, IKK is 
the only kinase identified as being directly involved in the phosphorylation 
of NT17 [20], although CK-2 inhibitors can also modulate its 
phosphorylation at Ser13/Ser16 [21]. To the best of our knowledge, no 
phosphatase has been identified to date as being responsible for the 
dephosphorylation of NT17. 
In this work, we generated transgenic flies expressing different 
mutant forms of Httex1 with the T3, S13 and S16 residues being either 
mutated to aspartate (D), mimicking the phosphorylated state 
(phosphomimetic), or to alanine (A), rendering them non-phosphorylatable 
(phosphoresistant) (Fig.3.1). With our new Drosophila tools, we intended 
to study the effects of the phosphorylation/dephosphorylation of T3, S13 
and S16 residues on the aggregation and toxicity of mutant Htt in vivo. 
Furthermore, we aimed to identify some of the phosphatases involved in 
the dephosphorylation of these residues, which may constitute a promising 





3.3.1. Cdc25 inhibitors prevent mutant huntingtin aggregation and 
regulate its phosphorylation 
The inhibition of certain kinases can modulate Htt N-terminal 
phosphorylation. For example, Casein kinase-2 inhibitors reduce 
N-terminal phosphorylation at S13 and S16, increasing the toxicity caused 
by mutant Htt and suggesting that phosphorylation of these residues has a 
protective role for cells [21]. IKK, a kinase involved in inflammatory 
response, directly phosphorylates Htt at S13 and S16, and it activates Htt 
clearance through the activation of proteasomal and lysosomal degradation 
mechanisms [20].  
However, nothing is still known about protein phosphatases 
modulating Htt N-terminal dephosphorylation and its effects in terms of 
mutant Htt oligomerization, aggregation and toxicity. Therefore, we 
intended to identify relevant phosphatases in the context of HD. 
Our collaborators used a library of pharmacological inhibitors (Enzo 
Life Sciences) to test the effect of 33 phosphatase inhibitors on mutant Htt 
aggregation (Fig. 3.3). 





Figure 3.3. Cdc25 inhibitors prevent mutant huntingtin aggregation and regulate 
its phosphorylation in Human H4 glioma cells. (A) The effect of 33 phosphatase 
inhibitors (Enzo Life Sciences) on the aggregation mutant Htt, was tested by filter 
trap assays. Normal Htt does not produce aggregates (Not shown). Graph shows 
optic density readings from the immunoblot. PP1/PP2A, CD45 and Cdc25 
inhibitors showed the most consistent results, and were therefore selected for 
further analyses (B-D). (B) PP1/PP2A, CD45 and Cdc25 inhibitors reduced 
significantly the percentage of cells with aggregates. (C) However, no differences 
in the average number and size of aggregates were detected upon treatment with 
phosphatase inhibitors. (D) Western blot for total levels of Htt and phosphorylated 
Htt (anti phosho-Htt, Ambion), that recognizes phosphorylation at serines 13 and 




show the average ± standard deviation of three independent experiments. *, 
significant versus 97Q plus DMSO, p<0.05*. Scale bar, 20 µm. AU, arbitrary 
units. 
 
This approach led to the identification of inhibitors for 3 
phosphatases (Cdc25, PP1/PP2A and CD45) that decreased mutant Htt 
aggregation in mammalian cells. Inhibition of these phosphatases 
significantly reduced the percentage of cells with aggregates (Fig. 3.3B). 
However, in cells with Htt aggregates, no significant differences in the 
average number and size of aggregates were detected upon treatment with 
inhibitors for these phosphatases (Fig. 3.3C). Concerning the effect of the 
inhibitors in the phosphorylation of NT17 residues, only Cdc25 inhibitors 
produced an increase in Htt phosphorylation at S13 and S16 (Fig. 3.3D). 
For this reason, we decided to further characterize the effect of the Cdc25 
phosphatase in our Drosophila model for HD. 
 
  




3.3.2. Genetic knockdown of Cdc25 in Drosophila dopaminergic 
neurons reduced the aggregation of mutant Htt 
We decided to validate the results obtained in cell culture for Cdc25, 
by doing genetic knockdown experiments in Drosophila. We knocked 
down string, the Drosophila homologue for Cdc25, in the dopaminergic 




Figure 3.4. The genetic knockdown of string, Drosophila homologue for Cdc25, 
reduced the aggregation of mutant Htt in Drosophila dopaminergic (DA) neurons. 
(A) Protein aggregates generated by the expression of mutant Htt. Genotype: 
TH-GAL4, UAS-Htt97Q-mCherry. (B) The co-expression of the inert LacZ had 
no effect on Htt aggregation. Genotype: TH-GAL4, UAS-Htt97Q-mCherry/UAS-
LacZ. (C) The genetic knocking down of String promoted a significant reduction 







Expression of mutant Htt in DA neurons induced the accumulation 
of protein aggregates, as expected (Fig. 3.4A). Co-expressing mutant Htt 
with the string RNAi reduced Htt aggregation, validating the results 
obtained in mammalian cells (Fig. 3.4C). To exclude a non-specific effect 
of the string RNAi line, we induced the co-expression of mutant Htt with 
LacZ. The Htt/LacZ cross showed a phenotype similar to mutant Htt alone. 
This strongly indicates that the reduction in the aggregation of mutant Htt 
was specifically induced by specific inhibition of Cdc25 (Fig. 3.4B). 
Cdc25 is involved in the control of the cell-division cycle, by 
activating cyclin-dependent protein kinases (Cdks), through 
dephosphorylation events [22]. Therefore, Cdc25 induces the entry and the 
progression of the different phases of the cell cycle, including mitosis. 
Although Cdks are absent in post-mitotic differentiated adult neurons, it 
was previously demonstrated an increased activity of Cdc25 in brain 
samples from AD patients, suggesting a possible association between cell 
cycle misregulation and neurodegeneration [23]. Taking into account our 
results in living human cells and Drosophila, we think it would be relevant 








3.3.3. The phosphorylation of NT17 residues modulates the 
oligomerization and aggregation of mutant Htt in human H4 glioma 
cells and in Drosophila dopaminergic neurons 
Using human H4 glioma cells, we found by fluorescence 
microscopy that 97QHttex1-Venus BiFC pairs promptly oligomerized and 
generated inclusion bodies (Fig. 3.5A). By performing filter-trap assays 
and Native-PAGE, it was confirmed that the wild-type 19QHttex1-Venus 
BiFC pairs, when compared to the mutant (97Q) pairs, generated 
significantly less oligomeric species and did not accumulated as 
SDS-insoluble aggregates (Fig. 3.6). Remarkably, all single mutations 
mimicking the phosphorylated state of 97QHttex1 (T3D, S13D or S16D) 
completely inhibited the formation of large insoluble inclusion bodies in 
living cells (Fig. 3.5A and 3.6FT). This inhibitory effect in the aggregation 
of mutant Htt was not observed with phosphoresistant mutations (T3A, 
S13A and S16A), being the pattern of aggregation similar to non-mutated 
97QHttex1 pairs (Fig. 3.5 and 3.6). Native-PAGE analyses confirmed that 
all phosphomutants formed oligomeric species (Fig. 3.6). In order to test 
the effect of the phosphomutations in the neurotoxicity of mutant Htt, we 
performed a toxicity assay based on the levels of LDH release. We found 
that the T3D phosphomimic significantly reduced the neurotoxicity of 
mutant Htt, to equivalent levels of the wild-type (19Q) Htt (Fig. 3.5C). For 
the rest of the phosphomutants, we could not detect any significant 







Figure 3.5. Phosphorylation of NT17 residues abolishes the accumulation of large 
Htt aggregates in H4 cells. (A)  Cells were transfected with the indicated pairs of 
BiFC constructs and Htt aggregation was evaluated by fluorescence microscopy. 
The 97QHtt pair typically shows large aggregates in the cytosol. While the 
phenotype of phosphoresistant mutants resembles the 97QHtt wt phenotype, the 
phosphomimic mutants showed homogeneous fluorescence in the cytosol, with a 
total absence of aggregates. Scale bar, 20 μm. (B) Quantitative analyses of 
microscopy pictures showed that the phosphoresistant mutations increase the 
percentage of cells with aggregates (C) The toxicity assay analyzed by LDH 
release, revealed that only the phosphomimic T3D mutation induced a significant 
reduction in the toxicity levels. *, Significant versus non-mutated 97QHtt BiFC 
constructs, p<0.05. 





Figure 3.6. Phosphorylation of NT17 residues affects Htt oligomerization and the 
formation of large aggregates in H4 cells. Filter trap (FT) assays were consistent 
with microscopy results, showing that phosphomimic mutants do not produce 
SDS-insoluble aggregates. In the case of the S16D mutant, there is also a striking 
increase in the production of oligomeric species, as can be observed in 
native-PAGE conditions. Htt wt (19Q) did not produce SDS-insoluble aggregates 
or large amounts of oligomeric species. When transfected together phosphomimic 
97QHtt-V1 BiFC mutant and non-mutated 97QHtt-V2 BiFC constructs showed 
similar levels of SDS-insoluble aggregates but a mixed pattern in terms of 
oligomerization. 
 
We expanded these human cell studies by testing the effect of each 
single-residue phosphoresistant and phosphomimic versions of Htt in the 
levels of mutant Htt aggregation and neurotoxicity in Drosophila. 
Phosphoresistant mutants showed a slight tendency to generate a higher 
number of aggregates of smaller sizes, but the patterns of aggregation were 
very similar to non-mutated 97QHtt-mCherry, with protein aggregates 
present in the cytoplasm (Fig. 3.7 C,E,G). Phosphomimic mutants showed 






Figure 3.7. Phosphorylation of NT17 residues affects Htt aggregation in 
Drosophila dopaminergic (DA) neurons. (A) The wild-type version 
19Htt-mCherry did not generate inclusions. (B) The normal mutant 
97QHtt-mCherry accumulated as protein aggregates. (C, E, G) The 
phosphoresistant mutations T3A, S13A and S16A in the mutant Htt promoted the 
formation protein aggregates morphologically similar to the normal mutant 
version of Htt, although with a tendency to form smaller and a higher number of 
aggregates. (D, F, H) The phosphomimic mutations T3D, S13D and S16D 
promoted the formation of significantly larger aggregates when compared to the 
normal or to the phosphoresistant versions of mutant Htt. All the different versions 




Therefore, we demonstrated that single NT17 phosphorylation 
events affect the state of aggregation of muntant Htt. The next step 
consisted in evaluating the effect of these phosphorylation events in the 
motor abilities and survival of the flies, by performing climbing and 
survival assays. 
  




3.3.4. The dephosphorylation of NT17 residues induces motor 
dysfunction and life span decrease in Drosophila 
We evaluated the motor function and life span of flies expressing 
the different phosphomutant versions of mutant Htt in the central nervous 
system under the control of the nSyb-GAL4 driver (Fig. 3.8). 
Flies expressing mutant Htt containing the phosphoresistant 
mutations T3A, S13A and S13A showed a stronger and faster deterioration 
of their motor function when compared to the ones expressing the 
phosphomimic versions T3D, S13D and S16D or the normal version 
(non-phosphomutant) of mutant Htt (Htt97Q-mcherry) (Fig. 3.8A). 
Remarkably, flies expressing the T3D phosphomutant completely lost the 
geotactic response on the third week of the assay (approximately 26 
days-old flies). 
The expression of T3A, S13A and S16A mutant forms of Htt also 
induced a significant decrease in flies’ life span when compared to the rest 
of the genotypes tested (Fig. 3.8B). 
Interestingly, the decline of the motor functions and the increase of 
mortality both started at the same age (around the beginning of the third 
week), suggesting that these phenotypes are both consequence of the same 









Figure 3.8. The dephosphorylation of NT17 residues induced a strong impairment 
of flies’ motor abilities and an increase in the mortality. (A) The expression of 
mutant Htt (driven by nSyb-GAL4) containing the phosphoresistant mutations 
T3A, S13A and S16A induced a strong impairment of flies’ motor abilities 
compared to all the other genotypes tested, including the phosphomimic mutations 
T3D, S13D and S16D. The Y-axis represents the time (in seconds), it took for five 
males to climb 15 cm (mean ± SEM). Statistically significant values, comparing 
each of genotypes, were calculated by doing two-way ANOVA with Bonferroni 
post-test. (B) The expression of mutant Htt (driven by nSyb-GAL4) containing the 
phosphoresistant mutations T3A, S13A and S16A promoted a significant 
reduction of flies’ life span in comparison with the rest of the genotypes tested. 
The phosphomimic mutations T3D, S13D and S16D promoted a significant 
increase of flies’ longevity comparing to the normal (non-phosphomutant) mutant 
Htt (Htt97Q-mCherry). Values on the Y-axis represent the percentage of flies 
alive at each time point analyzed. 
 
  




However, our results clearly suggest a deleterious effect of NT17 
dephosphorylation since flies expressing the phosphoresistant mutant 
versions of Htt showed a faster and stronger progression of HD-like 
phenotypes, comparing to the rest of the genotypes tested. It seems that the 
dephosphorylation of mutant Htt may contribute for an enhancement of its 
toxicity, inducing an earlier onset and faster progression of HD. Therefore, 
phosphatases involved in the dephosphorylation of NT17 residues may 






The results obtained in this study suggest an important role of 
NT17 phosphorylation in HD. We presented evidence that single NT17 
phosphorylation events can modulate mutant Htt aggregation and that the 
final outcome of this modulation depends on the biological context.  
Previous studies demonstrated a protective effect of double 
phosphorylation events at S13 and S16 in the context of HD [18, 24]. 
Actually, despite single phosphorylation events are more common than 
double phosphorylation events [25], the majority of the works developed 
with the aim of investigating the effect of the NT17 phosphorylation on 
mutant Htt aggregation and neurotoxicity have focused on double 
phosphorylation events at S13 and S16. The occurrence of these double 
phosphorylation events would implicate high levels of specific kinases, 
only possible by their overexpression [20]. Additionally, previous studies 
also demonstrated that both single and double S13 and S16 
phosphorylation similarly inhibit mutant Htt aggregation in vitro [24]. 
Therefore, we decided to direct our efforts to investigate the therapeutical 
potential of single NT17 phosphorylation events in cells and in vivo, and 
to identify phosphatases involved in this process, which we believe to be a 
more promising approach. 
Although our study is not the first one to specifically focus on 
single phosphorylation events at T3, S13 and S16 residues [21, 26], it is 
the only one to address the effect of these events on the aggregation and 
neurotoxicity of mutant Htt. We developed our study in two different 
systems, one using human cells in culture, and other using a new 
Drosophila model for HD. In living cells, we found that all the 
phosphomimic mutations (T3D, S13D and S16D) abolished the 
aggregation of mutant Htt, which is consistent with previous works 
demonstrating an inhibitory effect of NT17 phosphorylation in mutant Htt 




aggregation [24]. In contrast, in our Drosophila model for HD, these 
phosphomimic mutations had the opposite effect in terms of mutant Htt 
aggregation, enhancing it, which is partially coherent with a previous study 
in Drosophila where it was also observed that the phosphomimic mutation 
T3D enhanced aggregation of mutant Htt, while the T3A mutation slightly 
reduced it [19]. Interestingly, in our fly model, we found that higher levels 
of mutant Htt aggregation and the formation of bigger aggregates were 
correlated with a reduction in the neurotoxicity. 
With our work we also found that the inhibition of specific protein 
phosphatases resulted in lower aggregation of mutant Htt. Specifically, the 
inhibition of Cdc25 promoted a reduction of mutant Htt aggregation, both 
in human H4 cells and in Drosophila DA neurons. We are currently 
interested in identifying the specific residues in the NT17 which are 
substrate to the action of the phosphatases identified in our study as being 
modulators of mutant Htt aggregation. 
Despite the contradictory observations in our study, concerning 
mutant Htt aggregation and toxicity, depending on the model used, we 
demonstrated that single NT17 phosphorylations are sufficient to modulate 
mutant Htt aggregation and neurotoxicity. Moreover, our work suggests 
that the neurotoxicity of mutant Htt could be efficiently modified by NT17 
phosphorylation independently of its effect on protein aggregation. We 
hope that the continuation of this study could consistently establish NT17 




3.5. Material and Methods 
Cell culture and BiFC plasmids 
Human H4 glioma cells (ATCC HTB-148, LGC Standards, 
Barcelona, Spain) were maintained in OPTI-MEM I medium 
supplemented with 10% fetal bovine serum and penicillin/streptomycin 
(1%), under controlled conditions of temperature and CO2 (37oC, 5% 
CO2). All reagents were purchased from Gibco (Invitrogen, Barcelona, 
Spain). For all the experiments, cells were seeded at a density of 10.000 
cells/cm2. Depending on the analytical method, cells were seeded on 
different types of plates. The density was maintained among the different 
sizes of plates in order to obtain comparable results with different 
techniques. For flow cytometry and toxicity assays, cells were grown on 6-
well plates (Techno Plastic Cultures AG, Switzerland) and seeded in 
duplicate for each experimental group (2 wells per group). For 
microscopy, cells were seeded on glass- bottom 35 mm dishes (MatTek 
Corporation, Ashland, MA, USA). For protein extraction (PAGE and filter 
trap assays) cells were seeded in 100 mm dishes (Techno Plastic Cultures 
AG, Switzerland). Twenty-four hours later, X-tremeGene 9 DNA 
transfection reagent (Roche diagnostics, Mannheim, Germany) was used to 
transiently transfect cells with the different combinations of plasmids, 
according to the manufacturer’s instructions. We and others have observed 
that 97QHtt expression is much less efficient than 19QHtt expression, 
resulting in impaired protein levels when cells are transfected with the 
same amount of plasmid. Such expression differences cause biased 
experimental results, 19QHtt being more toxic and producing more 
aggregates than 97QHtt. In order to correct this, 97QHtt-Venus 
(phosphomutants and nonmutated plasmids) and 19QHtt-Venus BiFC 
plasmids were used in an approximate proportion of 1:6, as previously 




described (Herrera et al., 2011). Twenty-four hours after transfection, cells 
were handled according to the requirements of each analytical method. 
 
Drosophila stocks 
We generated eight constructs each encoding different versions of  
UAS-Htt-mCherry lines: one encoding a wild-type version of Htt with a 19 
polyQ tail, another encoding a mutant version of Htt with a 97 polyQ tail, 
and the other six encoding phosphomutant versions (T3A/D, S13A/D and 
S16A/D) of Htt also containing a polyQ tract with 97 glutamines. We 
cloned these constructs into pWalium10-roe, using the Gateway cloning 
technology (Thermo Fisher Scientific, USA). The transgenic lines were 
generated using phiC31 integrase-mediated DNA integration (BestGene 
Strain #9723, attP acceptor site in 28E7). Two different drivers were 
obtained from the Bloomington Stock Center (Indiana University, 
Bloomington, IN, USA): TH-GAL4 (active in DA neurons, under the 
control of the tyrosine hydroxylase promoter) and nSyb-GAL4 (active in 
the entire nervous system, under the control of the Synaptobrevin 
promoter). Drosophila stocks were maintained at 19°C on standard 
cornmeal media in an incubator with a 12 h light/dark cycle. 
 
Immunohistochemistry and microscopy 
Brain preparations for confocal microscopy imaging were done as 
previously described [27]. Briefly, adult flies were anesthetized with CO2 
and the brains were isolated from the head cuticles and fixed in phosphate 
buffered saline (PBS) containing 4% paraformaldehyde. 
DA neurons were stained by incubation for 48 h at 4°C with mouse 
anti-TH antibody (Immunostar, Hudson, WI, USA) diluted 1:50 in PBST 
(1× PBS + 0.3% Triton X-100) containing 5% (v/v) normal goat serum. 




secondary anti-mouse Cy5 (Jackson ImmunoResearch), also diluted in 
PBST-containing 5% (v/v) normal goat serum. Brain samples were 
analyzed and images were collected using a LSM 710 Meta Zeiss confocal 
microscope. Images were acquired with a resolution of 1024 × 1024, with 
a slice thickness of 1 µm and a line-average of 4. Z-projections were 




Western blotting analyses were performed using equivalent amounts 
of protein (15 μg) from the different extracts tested. Protein extraction was 
done under denaturing or native conditions for western blots and filter 
traps, respectively. For denaturing conditions, the samples were boiled for 
5 min at 95 ºC in a denaturing loading buffer (200 mM Tris-HCl pH 6.8; 
8% SDS; 40% glycerol; 6.3% β-mercaptoethanol; 0.4% bromophenol 
blue). Subsequently, the samples were resolved on a 12% SDS-
polyacrylamide gel by electrophoresis. For native conditions, the samples 
were resuspended and lysed in SDS- and mercaptoethanol-free loading 
buffer (200 mM Tris-HCl pH 6.8; 40% glycerol; 0.4% bromophenol blue) 
and they were not boiled. Then the samples were directly loaded and run 
on 5% Native (SDS-free)-polyacrylamide gels. After electrophoresis, the 
proteins were transferred onto PVDF membranes using the Trans-Blot 
TurboTM Transfer Starter System (Bio-rad, Hercules, CA, USA). 
Posteriorly to the transfer, in order to confirm the efficiency of the protein 
transfer and the equal loading of the samples, a Ponceau S staining was 
performed on membranes. The membranes were incubated on blocking 
solution [5% non-fat dry milk in Tris-HCl buffer saline-Tween with a 
(TBS-T) (150 mM NaCl, 50 mM Tris pH 7.4, 0.5% Tween-20)] for 1 hour 
at room temperature and with agitation. Membranes were then incubated 




with the appropriate dilution of primary antibodies in a solution of 5% 
bovine serum albumin (BSA) in TBS 1X (150 mM NaCl, 50 mM Tris pH 
7.4) and 0.05% of sodium azide. The mouse monoclonal Htt antibody 
(Millipore, Billerica, MA, USA) was incubated in a 1:500 dilution 
overnight at 4 ºC and with agitation. The mouse monoclonal GAPDH 
antibody (Ambion, Austin, TX, USA) was incubated for 1 hour at room 
temperature with agitation in a dilution of 1:30000. Membranes were then 
washed 3 times in TBS-T and incubated with a secondary mouse IgG 
Horseradish Peroxidase-linked antibody (GE Healthcare Life Sciences, 
Uppsala, Sweden), diluted in 5% non-fat dry milk in TBS-T, under the 
following conditions: 1:5000 for 2-3 hours (for Htt) or 1:40000 for 30 min 
(for GAPDH) at room temperature and with agitation. Membranes were 
washed 3 times in TBS-T and the immunoblot signal was revealed using 
enhanced chemiluminescence reagents (Millipore, Billerica, MA, USA) 
and visualized after exposition to autoradiographic films. 
 
Filter trap assay 
Protein extracts were obtained in native conditions, as described 
above, and SDS was added to 100 μg of each extract to a final SDS 
concentration of 0.4% (w/v). The samples were passed through cellulose 
acetate membranes (0.22 μm pore; GE Water & Process Technologies, 
Fairfield, CT, USA) by vacuum, using a dot blot device. Cellulose acetate 
membranes were previously incubated with PBS 1X and 1% (w/v) SDS 
solution. Posteriorly to the filtration step, 2 washing steps were carried out, 
using a PBS 1X and 1% (w/v) SDS solution to clean the wells; and 
membranes were treated with the blocking solution, and incubated with 
antibodies as described above. The chemiluminescence detection was done 





Climbing assays and survival assays 
Motor function was analyzed by startle-induced locomotion and 
negative geotaxis response assays, commonly called climbing assays, as 
previously described [28]. Briefly, groups of 10 males of the same age of 
each genotype of interest were placed into 18-cm-long vials, at room 
temperature for environmental acclimatization, and 30 min later they were 
gently tapped to the bottom of the vial (a minimum number of 30 males 
per genotype was tested). We recorded the climbing time when five flies 
crossed the 15-cm finish line. For each genotype we tested three 
independent groups of males and performed five trials for each time point. 
Results are the average climbing time ± SEM of these independent 
experiments.  
For survival assays, flies were maintained in a humid incubator at 
19°C under a 12 h light/dark cycle. Thirty adult females of the same age 
were placed in three vials (10 flies per vial) containing fresh food. Each 3 
days the flies were transferred into vials with fresh food and the number of 
living flies was registered. 
 
Statistical analysis 
Statistical analyses were done using GraphPad Prism software 
version 5 (San Diego, CA, USA). For BiFC, we performed a One-way 
ANOVA followed by a post-hoc Tukey test for average comparison. For 
climbing assays, we performed a Two-way ANOVA followed by a 
Bonferroni post-test.  For the survival assays, we performed a Log-rank 
(Mantel-Cox) test. 
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Protein misfolding and aggregation is a major hallmark of 
neurodegenerative disorders such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD) and Huntington’s disease (HD). Until recently, 
the consensus was that each aggregation-prone protein was characteristic 
of each disorder [α-synuclein (α-syn)/PD, mutant huntingtin (Htt)/HD, Tau 
and amyloid beta peptide/AD]. However, growing evidence indicates that 
aggregation-prone proteins can actually co-aggregate and modify each 
other’s behavior and toxicity, suggesting that this process may also 
contribute to the overlap in clinical symptoms across different diseases. 
Here, we show that α-syn and mutant Htt co-aggregate in vivo when co-
expressed in Drosophila and produce a synergistic age-dependent increase 
in neurotoxicity associated to a decline in motor function and life span. 
Altogether, our results suggest that the co-existence of α-syn and Htt in the 
same neuronal cells worsens aggregation-related neuropathologies and 





The presence of protein aggregates in the brain is a common 
hallmark for several neurodegenerative diseases, such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). 
The specific subcellular location and composition of protein aggregates are 
characteristics for each disorder. PD hallmarks are the formation of Lewy 
bodies, intracytoplasmic inclusions of misfolded proteins containing 
mainly α-synuclein (α-syn) and the demise of dopaminergic neurons in the 
substantia nigra. In AD, deposits of amyloid-beta and tau proteins in the 
brain lead to hippocampal degeneration, cognitive impairment and 
dementia. In HD, mutant huntingtin (Htt) with polyglutamine (polyQ) 
repeat expansion accumulates in cytoplasmic and intranuclear aggregates 
leading to neurodegeneration in the striatum [1]. 
Although each neurodegenerative disorder has its characteristic 
pathophysiology, current evidence indicates that there is also significant 
overlap between apparently different disorders. For example, α-syn is the 
protein that characteristically aggregates in PD, but it was originally 
discovered as a constituent of amyloid plaques in AD [2] and, later on, was 
found in protein aggregates in diverse pathologies of the central nervous 
system, such as HD, trisomy of chromosome 21, progressive supranuclear 
palsy and frontotemporal dementia [3-7]. Tau, an AD-associated protein, 
was detected in protein aggregates in patients with PD, sporadic dementia 
with Lewy bodies and multiple system atrophy, as well as in some animal 
models for synucleinopathies [8-14]. 
This apparent convergence of the molecular and cellular phenomena 
is accompanied by an overlap in the symptoms. For instance, patients 
suffering from diseases that affect movement control and coordination, as 
is the case of PD and HD, may also exhibit dementia in more advanced 
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stages of disease [15]. Conversely, patients afflicted by dementia can also 
show PD- or HD-like motor symptoms [16]. 
There is growing evidence that co-occurrence of aggregate-prone 
proteins may decisively influence the pathophysiology and severity of 
neural disorders. Tau and α-syn interact and co-aggregate, and this is 
associated with an increase in neurotoxicity in cellular and Drosophila 
models [17, 18]. Htt has been recently shown to co-aggregate with proteins 
associated with synucleinopathies and tauopathies [19-22]. Mutant Htt 
induces Tau hyperphosphorylation and aggregation, preventing its 
association to the microtubular network and producing large ring-like 
aggregates close to the microtubular network [19, 20]. DJ-1, which is 
associated with familial PD, interacts and co-aggregates with α-syn and 
Htt, modulating their toxicity in models of PD and HD [20, 22]. 
We have previously shown that α-syn modifies the dynamics and 
aggregation pattern of mutant Htt in cells in culture [23]. Here, we expand 
those studies and report that co-existence of α-syn and mutant Htt in vivo 
strongly enhances PD- and HD-related neuropathology in Drosophila 
melanogaster, suggesting that the interplay between the two proteins 






4.3.1. Co-expression of mutant Htt and α-syn alters Htt aggregation 
pattern 
Expression of normal (25Q) Htt or α-syn bimolecular fluorescence 
complementation (BiFC) pairs in human (H4) cells produced mostly 
homogeneous fluorescence, Htt being more often restricted to the cytosol 
and α-syn spreading both through nucleus and cytosol (Fig. 4.1A). On the 
other hand, mutant (103Q) Htt BiFC pairs produced protein aggregates. 
The combination of mutant Htt/α-syn also produced aggregates, but they 
seemed fewer and larger than pure 103Q aggregates. This was confirmed 
quantitatively (Fig. 4.1B–D), as the number of aggregates per cell was 
reduced 2-fold in mutant Htt/α-syn combinations (Fig. 4.1B), and the 
number of cells with <10 aggregates grew at the expense of cells with >25 
aggregates (Fig. 4.1C). Finally, the percentage of aggregates larger than 3 
µm increased in mutant Htt/α-syn combinations at the expense of 
aggregates smaller than 1 µm (Fig. 4.1D). The proportion of cells with 10–
25 aggregates and of aggregates between 1 and 3 µm remained unchanged. 
Both mutant Htt and α-syn increased cell death 24 h after 
transfection of H4 cells with the corresponding combinations of BiFC 
constructs (Fig. 4.1E). However, and in spite of the clear changes induced 
by α-syn on mutant Htt aggregation pattern, we did not observe changes at 
the viability level, even 72 h after transfection (data not shown). Longer 
experiments are extremely difficult to carry out in this experimental setup. 
 




Figure 4.1. Co-expression of mutant Htt and α-syn alters Htt aggregation pattern. 
(A) H4 cells transfected with different combinations of α-syn- and Htt-Venus 
BiFC constructs. Cells transfected with a Htt25Q-Venus BiFC pair of plasmids 
show homogeneous fluorescence indicative of oligomeric species, while a 
Htt103Q-Venus BiFC pair produces both oligomeric species and large 
intracellular fluorescent aggregates with variable size and morphology. Htt 
location is primarily cytosolic. α-Syn-Venus BiFC pair produces homogeneous 
fluorescence distributed throughout all cellular compartments, including the 
nucleus. When α-syn and Htt103Q BiFC constructs were combined, there is a 
change in the aggregation pattern of both proteins, quantified in B–D. Co-
transfection of Htt103Q with α-syn BiFC constructs decreases the average number 
of aggregates per cell (B and C) and increases the average size of aggregates (D). 
(E) The α-syn pair or the Htt103Q pair are more toxic than the wild-type Htt pair 
and combining α-syn with Htt103Q does not enhance toxicity in this model. 
*Significant versus 103Q/103Q, P< 0.01; # Significant versus 25Q/25Q, P< 0.001. 




4.3.2. Htt103Q-mCherry and α-syn-EGFP co-localize and 
co-aggregate in dopaminergic neurons and in photoreceptors 
In order to confirm our results with human cells in culture and to be 
able to measure neurotoxic effects of Htt/α-syn combinations during 
longer periods of time, we performed assays using transgenic 
overexpression in Drosophila. Co-expression of a mutant version of Htt 
containing 103 glutamines (Htt103Q-mCherry) and wild-type α-syn-EGFP 
in dopaminergic neurons (TH-GAL4) showed co-localization and 
co-aggregation of these two proteins (Fig. 4.2), confirming our results in 
cultured human cells. In terms of subcellular location, we found that these 
α-syn-EGFP/Htt103Q-mCherry aggregates accumulate both in cell bodies 
(Fig. 4.2A) and neurites (Fig. 4.2B) of dopaminergic neurons. In contrast, 
flies co-expressing α-syn-EGFP with a wild-type version of Htt 
(Htt25Q-mCherry) do not show aggregates (Fig. 4.2C), suggesting that 
only mutant Htt stimulates the deposition of α-syn in these aggregates. 
Flies expressing α-syn-EGFP or wild-type Htt25Q-mCherry alone did not 
show aggregates (Fig. 4.2D and E). 




Figure 4.2. Htt103Q-mCherry and α-syn-EGFP co-localize and co-aggregate when 
expressed in dopaminergic neurons. (A) Co-localization of Htt103Q-mCherry and 
α-syn-EGFP aggregates in cell bodies of dopaminergic neurons (arrows). 
(B) Co-localization of Htt103Q-mCherry and α-syn-EGFP aggregates in neurites 
of dopaminergic neurons (arrows). (C) Wild-type Htt (Htt25Q-mCherry) does not 
form aggregates with α-syn-EGFP. (D and E) The expression of α-syn-EGFP 
alone or Htt25Q-mCherry does not induce the formation of aggregates. The 
images in A–E show dopaminergic neurons in the paired posterior lateral 1 (PPL1) 
cluster marked by an anti-TH antibody (against tyrosine hydroxylase). Genotypes: 
(A, B) TH-GAL4, UAS-α-syn-EGFP/UAS-Htt103Q-mCherry, (C) TH-GAL4, 
UAS-α-syn-EGFP/UAS-Htt25Q-mCherry, (D) TH-GAL4, UAS-α-syn-EGFP and 




Using sGMR-GAL4 we induced the co-expression of Htt103Q-
mCherry and α-syn-EGFP in eye imaginal discs of third instar larvae 
(Fig. 4.3). We observed co-localization and co-aggregation of α-syn and 
mutant Htt in the cytoplasm of the photoreceptors (Fig. 4.3A and A′), and 
also in the axonal projections of the photoreceptors in the larval brain (Fig. 
4.3B). 
 
Figure 4.3. Htt103Q-mCherry and α-syn-EGFP co-localize and co-aggregate in 
the eye discs of third instar larvae. (A) Third instar larval eye disc from double 
transgenics stained with the pan-neuronal marker anti-elav. α-Syn-EGFP 
co-localized and co-aggregated with Htt103Q-mCherry aggregates in the 
cytoplasm of larval photoreceptors. (A′) Magnified area delimited by the box in 
(A). Arrows indicate foci of co-aggregated proteins. (B) Htt103Q-mCherry and α-
syn-EGFP co-localized in the photoreceptors’ axonal projections in the larval 
brain. Genotype: sGMR-GAL4, UAS-α-syn-EGFP/UAS-Htt103Q-mCherry. Scale 
bars represent 10 µm. 
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4.3.3. Htt103Q-mCherry and α-syn-EGFP are physically interacting 
Mutant Htt103Q-mCherry was co-immunoprecipitated with α-syn-
EGFP, using an antibody against the green fluorescent protein (GFP) tag, 
further demonstrating that mutant Htt103Q-mCherry and α-syn-EGFP 
interact and co-aggregate in Drosophila cells (Fig. 4.4A). In order to 
analyze the solubility status of these proteins when they are co-expressed, 
we performed a Triton-X solubility experiment using protein extracts from 
8 days old adult heads. We found that the levels of α-syn-EGFP and 
Htt103Q-mCherry in the Triton insoluble fraction increased when these 
proteins are co-expressed, in comparison when they are expressed alone 
(Fig. 4.4B). This result indicates that co-expression of α-syn-EGFP and 
Htt103Q-mCherry causes an increase in the formation of insoluble 









Figure 4.4. Htt103Q-mCherry and α-syn-EGFP are physically interacting. (A) 
Immunoprecipitation of α-syn-EGFP with an antibody against the EGFP tag 
pulled down Htt103Q-mCherry from dopaminergic neurons, showed by 
immunoblotting analysis. (B) Immunoblotting of Total, Triton-X soluble and 
Triton-X insoluble fractions of α-syn-EGFP and Htt103Q-mCherry from adult 
heads of flies co-expressing these two proteins. The levels of α-syn-EGFP and 
Htt103Q-mCherry in the insoluble fraction are higher when these proteins are 
co-expressed. Genotypes: (A) TH-GAL4, UAS-α-syn-EGFP/UAS-Htt103Q-
mCherry. (B) α-Syn: sGMR-GAL4, UAS-α-syn-EGFP. Htt103Q: sGMR-GAL4, 
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4.3.4. Co-expression of Htt103Q-mCherry and α-syn-EGFP produces 
premature and severe degeneration in the photoreceptors 
Next, we expressed Htt103Q-mCherry and α-syn-EGFP in the eye 
using sGMR-GAL4 and analyzed the external morphology of the adult eye 
in 8 days old flies (Fig. 4.5A–D). Expression of the GFP tag alone had no 
effect on eye development or viability as the eyes looked normal 
(Fig. 4.5A). Flies expressing α-syn-EGFP alone also developed a normal 
eye, identical to control flies (Fig. 4.5B). On the other hand, flies 
expressing mutant Htt103Q-mCherry, alone or in combination with α-syn-
EGFP, showed striking retinal degeneration, producing a strong rough eye 
phenotype (Fig. 4.5C and D). Co-expression of mutant Htt103Q-mCherry 
and α-syn-EGFP did not worsen the rough eye phenotype in comparison 
with Htt103Q-mCherry alone. However, co-expression of Htt103Q-
mCherry and α-syn-EGFP specifically in the photoreceptors R1–R6, using 
Rh1-GAL4, showed a stronger and premature degeneration phenotype 
(Fig. 4.5G) in comparison with Htt103Q-mCherry alone (Fig. 4.5H). In 
this case, control GFP or α-syn-EGFP alone did not show any degeneration 
phenotype (Fig. 4.5E and F). These results indicate that co-expression of 
α-syn-EGFP and mutant Htt103Q-mCherry enhances neurodegeneration of 






Figure 4.5. Co-expression of Htt103Q-mCherry and α-syn-EGFP produces 
premature and severe degeneration in the photoreceptors. (A–D) External 
morphology of the adult eye. (A and B) Expression of GFP or α-syn-EGFP does 
not affect external eye morphology. (C and D) Co-expression of Htt103Q-
mCherry and α-syn-EGFP produces a rough eye phenotype identical to the one 
induced by the single expression of Htt103Q-mCherry. (E–H) Photoreceptors 
neurodegeneration in the adult eye, analyzed by water immersion microscopy 
assay of the retinas. (E) Expression of GFP did not induce degeneration of the 
photoreceptors, with the six photoreceptors being present in the ommatidial 
clusters; (F, G) flies expressing α-syn-EGFP or Htt103Q-mCherry showed 
progressive degeneration of the photoreceptors. (H) Co-expression of Htt103Q-
mCherry and α-syn-EGFP induced severe and early degeneration of the 
photoreceptors. Genotypes are indicated in the boxes on top and lateral of the 
figures: (A) sGMR-GAL4, UAS-GFP, (B) sGMR-GAL4, UAS-α-syn-EGFP, (C) 
sGMR-GAL4, UAS-Htt103Q-mCherry, (D) sGMR-GAL4, UAS-α-syn-
EGFP/UAS-Htt103Q-mCherry, (E) Rh1-GAL4, UAS-GFP, (F) Rh1-GAL4, UAS-
α-syn-EGFP, (G) Rh1-GAL4, UAS-Htt103Q-mCherry and (H) Rh1-GAL4, UAS-
α-syn-EGFP/UAS-Htt103Q-mCherry. Scale bars represent 50 µm (A–D) and 10 
µm (E–H). 
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4.3.5. Co-expression of Htt103Q-mCherry and α-syn-EGFP in the 
nervous system causes severe motor dysfunction and a decrease in life 
span 
We evaluated the motor function and life span of flies co-expressing 
mutant Htt103Q-mCherry and α-syn-EGFP in the central nervous system, 
using nSyb-GAL4 (Fig. 4.6). To test motor function we used “climbing 
assays”, where flies of different genotypes were tapped to the bottom of 
the vial and allowed to climb up the walls (Fig. 4.6A). We recorded the 
climbing time when 5 flies crossed a 15-cm finish line. Eight days old flies 
co-expressing Htt103Q-mCherry and α-syn-EGFP took, on average, 4 
more seconds to reach the finish line than the other genotypes tested. The 
motor abilities of Htt103Q-mCherry/α-syn-EGFP co-expressing flies 
deteriorated more and faster than the other genotypes, with the difference 
in climbing times reaching 32 seconds by day 30.  
Flies co-expressing Htt103Q-mCherry and α-syn-EGFP also showed 
a dramatic decrease in life span, with 44 days of maximum survival 
(Fig. 4.6B). Flies co-expressing Htt25Q-mCherry and a-syn-EGFP had a 
maximum survival of 71 days. Maximum survival of flies expressing GFP, 
α-syn-EGFP, Htt25Q-mCherry or Htt103Q-mCherry alone ranged from 59 
to 83 days. Interestingly, neurotoxicity, motor dysfunction and fly death 
started around days 8-15 and their increase occurred in parallel, indicating 
an association between these events. These results suggest that 
co-expression of α-syn and mutant Htt synergistically enhances each 





Figure 4.6. Co-expression of Htt103Q-mCherry and α-syn-EGFP in the nervous 
system causes severe motor dysfunction and a decrease in life span. (A) Flies 
co-expressing Htt103Q-mCherry and α-syn-EGFP under the control of nSyb-
GAL4 show a strong impairment of the motor abilities compared with the rest of 
the genotypes tested. The Y-axis represents the time (in seconds), it took for five 
males to climb 15 cm (mean ± SEM). Statistically significant values, comparing 
each of genotypes, were calculated by doing two-way ANOVA with Bonferroni 
post-test. With very few exceptions, all the differences detected between the 
Crosstalk between Parkinson’s and Huntington’s diseases 
141 
 
genotypes tested in this assay were statistically significant with a P< 0.001 (except 
the difference between the genotypes Htt25Q-mCherry and α-Syn-EGFP/Htt25Q-
mCherry which is significant for a P< 0.01). The differences not statistically 
significant (P> 0.05) were GFP versus Htt25Q-mCherry at day 13; α-Syn-EGFP 
versus Htt103Q-mCherry at day 13; α-Syn-EGFP versus α-Syn-EGFP/Htt25Q-
mCherry at days 24 and 30; Htt103Q-mCherry versus α-Syn-EGFP/Htt25Q-
mCherry at day 8. (B) Flies co-expressing Htt103Q-mCherry and α-syn-EGFP 
under the control of nSyb-GAL4 have a life span significantly shorter in 
comparison with the rest of the genotypes tested. Values on the Y-axis represent 
the percentage of flies alive at each time point analyzed. The maximum survival 
(in days) is indicated for each genotype (the mean values indicate the number of 
days it took for half of the flies to die): control (nSyb-GAL4) 83 (mean = 70), 
GFP (nSyb-GAL4, UAS-GFP) 77 (mean = 64), α-syn-EGFP (nSyb-GAL4, UAS-
α-syn-EGFP) 68 (mean= 45), Htt25Q-mCherry (nSyb-GAL4, UAS- Htt25Q-
mCherry) 74 (mean= 56), Htt103Q-mCherry (nSyb-GAL4, UAS-Htt103Q-
mCherry) 59 (mean = 44), α-syn-EGFP/Htt25Q-mCherry (nSyb-GAL4, UAS-α-
syn-EGFP/UAS-Htt25Q-mCherry) 71 (mean= 50) and α-syn-EGFP/Htt103Q-
mCherry (nSyb-GAL4, UAS-α-syn-EGFP/UAS-Htt103Q-mCherry) 44 (mean= 





Here, we show that α-syn and mutant Htt, two proteins associated 
with PD and HD, respectively, can interact and co-aggregate in vivo. 
Furthermore, their co-expression produced a synergistic deterioration of 
neural tissue, motor function and life span in Drosophila. The effects of 
α-syn/Htt co-expression under the different promoters are summarized in 
Table 1. While co-expression of other proteins associated with human 
neurodegenerative diseases have also shown deleterious effects in different 
models [17, 18, 23, 24], this is the first demonstration that co-expression of 
α-syn and mutant Htt can enhance neurodegeneration in Drosophila. 
 
Table 4.1. GAL4 lines used in this study and respective phenotypes. 
GAL4 line Tissue Phenotype (co-expression of α-syn and mutant Htt) 
TH-GAL4 Dopaminergic neurons 
Co-localization, interaction and co-aggregation of 
α-syn and Htt 
nSyb-GAL4 Nervous system Impairment of motor abilities and reduced life span 
sGMR-GAL4 Eye Co-localization, co-aggregation and retinal degeneration 
Rh1-GAL4 Photoreceptors R1-R6 Premature degeneration of the photoreceptors 
 
Our results support the idea that the co-occurrence of these two 
different aggregation-prone proteins in neural cells can produce striking 
changes in the pathology, symptoms and disease progression. Moreover, 
our study may give some clues why some patients suffering with a specific 
neuropathology may show, at the symptomatic level, a significant overlap 
between different human neurodegenerative diseases. It is possible that a 
HD patient containing a mutant version of the Htt gene (expansion of the 
trinucleotide CAG) and thereby suffering from the consequences of mutant 
Htt aggregation and toxicity, may be also in risk of developing aggregation 
of α-syn and therefore being affected by some of the symptoms associated 
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with PD. This could occur as a consequence of the propensity of mutant 
Htt and α-syn to interact, co-aggregating and interfering with their normal 
biological roles in cells. In addition, the two most affected brain regions in 
patients with PD and HD, the substantia nigra and striatum, respectively, 
are anatomically and functionally interconnected, reinforcing the interest 
of studying the crosstalk between these two neuropathologies. Finally, the 
models established in this work may constitute useful tools to screen and 




4.5. Material and Methods 
Cell culture and BiFC plasmids 
Maintenance of H4 human glioma cells and Htt and α-syn BiFC 
constructs were previously described in detail [23, 25]. Briefly, in our 
BiFC systems, Htt and α-syn were fused to two non-fluorescent halves of 
the Venus protein (Venus 1, amino acids 1–157; and Venus 2, amino acids 
158–239). When the Htt and α-syn dimerize, the Venus halves get together 
and reconstitute a functional fluorophore. Fluorescence is therefore 
proportional to the amount of Htt/α-syn dimers and oligomers. H4 cells 
were transfected with the corresponding BiFC pairs and 24 h later pictures 
were taken on a Zeiss Axiovert200M. A total of 150 cells from three 
independent experiments were analyzed. Graphs of Figure 1 show 
mean ± SD of three independent experiments. 
 
Drosophila stocks 
To generate UAS-α-Syn-EGFP, we fused α-syn with EGFP and 
cloned into pUAST using the BglII and Acc65I restriction sites. The 
transgenic flies were generated by BestGene, USA. We generated two 
different UAS-Htt-mCherry lines, one encoding a wild-type version of Htt 
(exon 1) with a 25 polyQ tail and the other encoding a mutant version of 
Htt with a 103 polyQ tail. These two constructs were cloned into 
pWalium10-roe and transgenic lines were generated using phiC31 
integrase-mediated DNA integration (BestGene Strain #9723, attP 
acceptor site in 28E7). Four different drivers were obtained from the 
Bloomington Stock Center (Indiana University, Bloomington, IN, USA): 
nSyb-GAL4 (active in the entire nervous system, under the control of the 
Synaptobrevin promoter), TH-GAL4 (active in dopaminergic neurons, 
under the control of the tyrosine hydroxylase promoter), GMR-GAL4 
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(active in the eye, under the control of the glass multiple reporter) and 
Rh1-GAL4 (active in the photoreceptors R1–R6, under the control of the 
rhodopsin1 promoter). Drosophila stocks were maintained at 25°C on 
standard cornmeal media in an incubator with a 12 h light/dark cycle. 
 
Immunohistochemistry and microscopy 
Brain preparations for confocal microscopy imaging were done as 
previously described [26]. Briefly, adult flies were anesthetized with CO2 
and the brains were isolated from the head cuticles and fixed in phosphate 
buffered saline (PBS) containing 4% paraformaldehyde. 
Dopaminergic neurons were stained by incubation for 48 h at 4°C 
with mouse anti-TH antibody (Immunostar, Hudson, WI, USA) diluted 
1:50 in PBST (1× PBS + 0.3% Triton X-100) containing 5% (v/v) normal 
goat serum. Three 10-min washes with PBST were done before incubation 
with a secondary anti-mouse Cy5 (Jackson ImmunoResearch), also diluted 
in PBST-containing 5% (v/v) normal goat serum. Brain samples were 
analyzed and images were collected using a LSM 710 Meta Zeiss confocal 
microscope. Images were acquired with a resolution of 1024 × 1024, with 
a slice thickness of 1 µm and a line-average of 4. Z-projections were 
generated using ImageJ and the images were processed using Adobe 
Photoshop.  
The degenerative effects caused by co-expression of α-syn and 
mutant Htt were assessed in the photoreceptors of adult eyes. To analyze 
external eye morphology, we used a Leica Z16 APO macroscope and a 
Leica DFC420C camera. To analyze photoreceptor degeneration, we 
performed water immersion microscopy as previously described [27]. 






Immunoprecipitation, Triton-X solubility and immunoblotting 
analysis 
Flies were transferred to 50-ml tubes, frozen in liquid nitrogen and 
immediately decapitated by vigorous vortexing. Isolated heads were 
collected to 1.5-ml tubes and maintained in dry ice. Proteins were 
extracted in lysis buffer supplemented with Complete Protease Inhibitor 
Cocktail tablets from Roche (Basel, Switzerland). Total protein was 
quantified using the DC Protein Assay, from Bio-Rad (CA, USA). In the 
immunoprecipitation experiments, α-syn-EGFP was pulled down from 
1  mg of total protein extract, using GFP-Trap_A beads or blocked agarose 
beads (No Ab, no antibody negative control), following manufacturer’s 
instructions (Chromotek, Munich, Germany). α-syn-EGFP pull-down and 
Htt103Q-mCherry co-immunoprecipitation were analyzed by 
immunoblotting using anti-GFP (3H9) and anti-RFP (5F8) antibodies from 
Chromotek, both diluted 1:1000 in PBS. Input lane corresponds to 30 µg 
of total protein extract and co-IP lane corresponds to one-fifth of the 
immunoprecipitated material. 
The Triton-X solubility experiment was performed as previously 
described [28]. Briefly, 200 µg of total protein extract was incubated with 
1% Triton X-100 on ice during 30 min. Triton soluble and insoluble 
proteins fractions were separated by a 60-min centrifugation step at 
15000g at 4°C. The supernatant, containing the soluble proteins fraction 
(Triton-X soluble), was carefully collected and the pellet, containing the 
insoluble proteins fraction (Triton-X insoluble), was resuspended in 40 µl 
of 2% sodium dodecyl sulfate Tris–HCl buffer pH 7.4 by pipetting and 
sonication for 10 s. For the immunoblotting analysis, equal volumes of 
each fraction were loaded and the presence of α-syn-EGFP and Htt103Q-
mCherry in the total, soluble and insoluble fractions was detected using 
anti-GFP (3H9) and anti-RFP (5F8). Additionally, anti-α-tubulin (AA4.3) 
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from Developmental Studies Hybridoma Bank (IA, USA), diluted 1:500 in 
PBS, was used as loading control. 
 
Climbing assays and survival assays 
Motor function was analyzed by startle-induced locomotion and 
negative geotaxis response assays, commonly called climbing assays, as 
previously described [29]. Briefly, groups of 10 males of the same age of 
each genotype of interest were placed into 18-cm-long vials, at room 
temperature for environmental acclimatization, and 30 min later they were 
gently tapped to the bottom of the vial (a minimum number of 30 males 
per genotype was tested). We recorded the climbing time when five flies 
crossed the 15-cm finish line. For each genotype we tested three 
independent groups of males and performed five trials for each time point. 
Results are the average climbing time ± SEM of these independent 
experiments. 
For survival assays, flies were maintained in a humid incubator at 
25°C under a 12 h light/dark cycle. Thirty adult females of the same age 
were placed in three vials (10 flies per vial) containing fresh food. Each 3 
days the flies were transferred into vials with fresh food and the number of 
living flies was registered. 
 
Statistical analysis 
Statistical analyses were done using GraphPad Prism software 
version 5 (San Diego, CA, USA). For BiFC we performed a One-way 
ANOVA followed by a post-hoc Tukey test for average comparison. For 
climbing assays, we performed a Two-way ANOVA followed by a 
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The accumulation of small organic molecules termed compatible solutes 
(CS) constitutes an efficient strategy, developed by organisms during 
biological evolution, to deal with extreme environmental and physiological 
changes, like fluctuations in the osmotic and/or temperature conditions. CS 
are efficient stabilizers, with potent chemical chaperone properties, 
protecting essential biomolecules from denaturation. Mannosylglycerate 
(MG) is one of the most common and efficient CS, widely found in 
hyperthermophile organisms. The biosynthesis of MG can be catalyzed by 
the bifunctional enzyme mannosylglycerate synthase (MGSD). The 
misfolding and aggregation of proteins constitutes a problem with strong 
biotechnological and medical relevance. In fact, the pathophysiology of 
several human neurodegenerative diseases, namely Parkinson’s (PD) and 
Huntington’s diseases (HD), is associated with the formation of protein 
aggregates containing misfolded proteins. Therefore, the strong stabilizer 
effects of CS on proteins have been investigated in order to explore the 
anti-aggregating and therapeutical potential uses of these compounds. The 
main aim of our study was to investigate the anti-aggregating and potential 
therapeutic effects of MG in Drosophila models for PD and HD expressing 
α-synuclein (α-syn) and huntingtin (Htt), respectively, and in a previously 
established model for Retinitis Pigmentosa (RP) expressing a mutant form 
of rhodopsin 1. We successfully generated transgenic lines expressing the 
bifunctional enzyme MGSD, but we could not detect the biosynthesis and 






Living organisms are frequently subjected to extreme changes in the 
normal environmental or physiological conditions, namely changes in 
water activity. The ability to deal with these changes, in order to maintain 
the biomolecules in a functionally folded state, is a crucial prerequisite for 
cell survival. One of the strategies developed by organisms during 
biological evolution consists in the accumulation, by import or de novo 
synthesis, of small molecules termed osmolytes [1-3]. Besides fluctuations 
in the osmotic pressure, some organisms are also exposed to extreme 
changes in the temperature and salinity of the environment, like the 
hyperthermophile marine microorganisms that thrive at high temperatures. 
These forms of life accumulate in the cells high levels, even at molar 
concentrations, of small organic molecules to counteract the perturbations 
in the thermodynamic conditions that would otherwise induce a partial or 
complete loss in the activity of essential biomolecules. Although these 
organic compounds accumulate in the cells to very high levels, frequently 
becoming the most abundant organic components in the cytoplasm, they 
preserve the native biological function of macromolecules in the cell, 
thereby earning the name of compatible solutes (CS) [4, 5]. There are 
several different molecules belonging to the group of these curious organic 
compounds, some of them depicted on Figure 5.1. These special CS, 
naturally occurring in organisms growing at temperatures near 100 ºC and 
rarely found in organisms living in moderate environments, are usually 
negatively charged and are one of the most potent stabilizers for proteins, 
acting as chemical chaperones, with the ability to reverse the protein 
misfolding and/or aggregation [6]. These properties contribute to an 
increasing interest and investment in the research related with ionic CS, at 
the biotechnological and biomedical levels. 




Figure 5.1. Examples of compatible solutes (CS) primarily restricted to 
hyperthermophile organisms. The molecular structures of these CS are shown. 
 
Several human pathologies, including neurodegenerative diseases, 
such as Parkinson’s (PD) and Huntington’s diseases (HD), are associated 
with protein misfolding and accumulation in aggregates. Furthermore, it 
has been shown that the folding of proteins with intrinsically disordered 
conformations, as it is the case of PD’s associated α-synuclein (α-syn), can 
be spontaneously induced by incubation with certain organic osmolytes, 
which promote the adoption of the native and functional form of these 
proteins [7, 8]. For these reasons, CS have been considered an attractive 
therapeutic target. There are some works in the literature stating for a 
potential therapeutic action of CS in the pathophysiology of some human 
diseases, as it is the case of trehalose (a disaccharide CS found in many 
microorganisms and invertebrates with the ability to protect the cell 
integrity against several environmental insults), which have shown 
promising therapeutic effects promoted by this CS on cellular and animal 
models of human neurodegenerative diseases [9, 10]. Mannosylglycerate 
(MG) is another very common CS produced by hyperthermophiles with a 




protein structures against thermal denaturation [11-14]. A recent work 
from our collaborators has shown the beneficial effect of MG against 
α-syn aggregation in a yeast model for PD [15]. Previous studies have 
shown that the stabilization properties of MG are associated with a protein 
rigidification effect, induced by a generalized reduction of very fast 
backbone motions by this CS [16, 17]. The misfolding, aggregation and 
accumulation of α-syn in Lewy bodies, an hallmark in the pathophysiology 
of PD, involves the formation of amyloid oligomers with a distinctive 
antiparallel β-sheet structure [18, 19]. Therefore, it is very tempting to 
speculate that the beneficial effect induced by MG might come from an 
inhibition in the fibrillation of α-syn through rigidification and 
stabilization of these β-sheet oligomers.  Our main goal with this work was 
to induce the in vivo biosynthesis and accumulation of MG in Drosophila, 
in order to test the anti-aggregating, re-folding and therapeutic properties 
of this CS in our Drosophila models for PD and HD, based on the 
expression of the prone-to-aggregate proteins α-syn and huntingtin (Htt), 
respectively. A previously established Drosophila model for Retinitis 
Pigmentosa (RP) was also used in our study [20]. Therefore, one of the 
main tasks of this work was to generate Drosophila transgenic lines 
expressing mannosylglycerate synthase (MGSD) [21], a bifunctional 
enzyme responsible for the synthesis of MG (Figure 5.2).  





Figure 5.2. Mannosylglycerate synthase (MGSD) is a bifunctional enzyme that 
catalyzes a two steps reaction responsible for the biosynthesis of 
mannosylglycerate (MG). MGSD uses 3-phosphate glycerate, an intermediate 
metabolite of glycolysis, as substrate of the enzymatic reaction. All the 








5.3.1. Expression of MGSD in Drosophila  
After the generation, by embryos transgenesis, of transgenic 
Drosophila lines for MGSD, we wanted to test if using the Gal4/UAS 
system we could induce the expression of this enzyme. By crossing the 
UAS MSGD lines with the pan-neuronal driver nSybGal4, we induced the 
expression of MGSD in the Drosophila nervous system. We proceeded 
with a protein extraction from these flies and we analyzed the expression 
of MGSD, at the protein level, by performing an immunoblot experiment, 
using a specific antibody for a homologue enzyme of MGSD [22].We 
successfully detected in the immunoblot a protein band with the expected 
molecular weight (77,9 kDa) for MGSD (Fig. 5.3). 
 
Figure 5.3. Expression of mannosylglycerate synthase (MGSD) in Drosophila, 
proved at the protein level by immunoblotting analysis. Protein extracts were 
obtained from four independent transgenic lines (numbered 1, 2, 5 and 7) 
expressing MGSD in the nervous system, under the control of the pan-neuronal 
nSybGal4 driver. For the immunoblotting we used a specific antibody for a 
homologue enzyme of MGSD [22]. The genotype of the transgenic Drosophila 
lines tested is indicated. Protein extracts from a genetically engineered yeast 
expressing MGSD were used as a positive control of the experiment. 
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We also tested the expression of MGSD protein, by performing an 
immunoflourescent assay in Drosophila eye imaginal discs. Using the 
lGMR Gal4 driver, we induced the expression of MGSD in the eye 
imaginal disc of third instar larvae and we proceeded with the 
immunostaining and confocal imaging of this tissue, using a specific 
antibody for a homologue enzyme of MGSD (and a secondary antibody 
conjugated with the Cy3 fluorescent die). We successfully detected the in 
vivo expression of MGSD in the Drosophila photoreceptors (Fig. 5.4).  
 
Figure 5.4. In vivo expression of mannosylglycerate synthase (MGSD) in the 
Drosophila photoreceptors. Immunoflourescent staining of third instar larvae eye 
discs, using a specific antibody for a homologue enzyme of MGSD [22] and a 
Cy3-conjugated secondary antibody. (A) MGSD expression was detected in the 
eye discs of flies expressing MGSD under the control of the lGMR Gal4 driver – 
Genotype: lGMR-GAL4, UAS-MGSD (B) MGSD was not detected in the eye 
discs of control flies expressing only Gal4 under the control of lGMR promoter 
(negative control) – Genotype: lGMR-Gal4. The nucleus of the photoreceptors 




Therefore, by immunoblotting and immunostaining analysis, we 
could prove, at the protein level, that using the Gal4/UAS system, we can 
successfully induce the expression of the bifunctional enzyme MGSD in 
Drosophila. 
 
5.3.2. The co-expression of MGSD reduced the ER stress levels in 
photoreceptors expressing ninaEG69D  
The point mutation G69D in ninaE, the gene that encodes 
Rhodopsin 1, causes accumulation of misfolded Rhodopsin 1 and leads to 
retinal degeneration. In a previous work [20], it was demonstrated that the 
expression of ninaEG69D in the Drosophila photoreceptors induces retinal 
degeneration like in human patients suffering from Retinitis Pigmentosa, 
and causes ER stress and activation of the Ire1/Xbp1 branch of the 
unfolded protein response (UPR). Here, we investigated the ability of MG 
to reduce the ER stress levels and promote the correct folding of ninaEG69D. 
We induced the co-expression of MGSD in the photoreceptors of third 
instar larvae expressing ninaEG69D, under the control of the lGMR Gal4 
driver, and we observed a reduction of the ER stress levels (Fig. 5.5). This 
reduction in the ER stress levels was assessed using the Xbp1-GFP 









Figure 5.5. The expression of mannosylglycerate synthase (MGSD) in our model 
for Retinitis Pigmentosa (RP) reduces the ER stress levels in the Drosophila 
photoreceptors expressing ninaEG69D. The ER stress levels were assessed using 
the Xbp1-GFP reporter. The activation of Xbp1-GFP was detected by the 
endogenous fluorescence of the GFP tag. The nucleus of the photoreceptors was 
stained by the pan-neuronal marker anti-elav. lGMR-GAL4 was the driver used in 
this experiment. (A) The expression of the mutant form of rhodopsin 1 (ninaEG69D) 
causes ER stress and induces the activation of the Xbp1-GFP reporter. Genotype: 
lGMR-GAL4/ UAS-Xbp1-GFP, UAS-ninaEG69D (B) The co-expression of MGSD 
in the photoreceptors expressing ninaEG69D promoted a reduction in the ER stress 
levels, as indicated by a reduction in the activation of the Xbp1-GFP reporter. 
Genotype: lGMR-GAL4/ UAS-Xbp1-GFP, UAS-ninaEG69D/UAS-MGSD. Scale 









5.3.3. MG was not detected in cellular extracts from Drosophila tissues 
expressing MGSD 
After confirming, by western blot and immunohistochemistry 
analysis, that we could successfully induce the expression of MGSD in our 
new transgenic UAS lines, and that the co-expression of MGSD alleviated 
the ER stress levels induced by the expression of ninaEG69D in the 
photoreceptors, we wanted to prove that MG was being synthesized in 
Drosophila. The experimental approach we used was to analyze the 
presence of MG in Drosophila extracts by thin layer chromatography 
(TLC) and nuclear magnetic resonance (NMR). We induced the expression 
of MGSD in different Drosophila tissues, using distinct Gal4 drivers (elav 
Gal4 and nSyb Gal4, active in the nervous system and Actin Gal4, active 
in the whole organism). Thus, we analyzed several cellular extracts 
produced from these Drosophila lines expressing MGSD in different 
tissues. We could not detect MG expression in any of these extracts, 
neither by TLC nor by NMR analysis (Fig. 5.6 and 5.7). 
We also performed an additional experiment where we co-expressed 
MGSD with a UAS RNAi line for phosphoglycero-mutase (Pglym78) in 
the Drosophila eye, using the sGMR-Gal4 driver. This experiment was 
done on the hypothesis that the genetic manipulation of the glycolytic 
pathway in order to increase the concentration 3-phosphate glycerate 
available in the cytoplasm to be enzymatically converted to MG by 
MGSD, would increase the chances of successfully produce MG in 
Drosophila. However, the analyses of the cellular extracts produced from 













Figure 5.6. The presence of mannosylglycerate (MG) in cellular extracts from 
Drosophila tissues expressing mannosylglycerate synthase (MGSD) could not be 
detected by thin layer chromatography (TLC) analysis. (A) The TLC analysis of 
cellular extracts from Drosophila lines (1, 2, 5 and 7) expressing MGSD in the 
nervous system, under the control of the pan-neuronal nSybGal4 driver, could not 
detect the presence of MG – Genotype: nSyb-GAL4, UAS-MGSD. (B) The TLC 
analysis of cellular extracts from Drosophila lines expressing MGSD in the whole 
organism, under the control of the ubiquitous Actin Gal4 driver, could not detect 
the presence of MG – Genotype: Actin-GAL4, UAS-MGSD. A pure solution of 
MG, cellular extracts from Rhodothermus marinus (Rm) a hyperthermophile 
microorganisms which accumulates MG and cellular extracts from yeast  
genetically modified to express mannosyl-3-phosphoglycerate synthase (MGPS) 






Figure 5.7. The presence of mannosylglycerate (MG) in cellular extracts from 
Drosophila tissues expressing mannosylglycerate synthase (MGSD) could not be 
detected by nuclear magnetic resonance (NMR) analysis. NMR analysis of 
Drosophila extracts was done for: (A) S2 cells transfected with the MGSD 
construct (pUAST MGSD), (B) Drosophila lines expressing MGSD in the 
nervous system, under the control of the pan-neuronal drivers elav Gal4, (C) 
Drosophila lines expressing MGSD in the nervous system, under the control of 
the pan-neuronal drivers nSyb Gal4 and (D) Drosophila lines expressing MGSD 
in the whole organism, under the control of the ubiquitous Actin Gal4 driver. The 
presence of MG could not be detected in none of the extracts tested. Genotypes: 
(A) pUAST MGSD, actin-Gal4 (B) elav-GAL4, UAS-MGSD, (C) nSyb-GAL4, 
UAS-MGSD (D) Actin-GAL4, UAS-MGSD. The green circles point for the 
detection of control MG, added to the extracts. The red circles point for the 
absence of detection of MG in the extracts tested. 
  




Figure 5.8. The presence of mannosylglycerate (MG) in cellular extracts from 
Drosophila tissues co-expressing mannosylglycerate synthase (MGSD) and RNAi 
for phosphoglycero-mutase (Pglmy78) could not be detected by nuclear magnetic 
resonance (NMR) analysis. (A) analysis of an extract produced from a Drosophila 
line co-expressing MGSD in the eye, under the control of sGMR-Gal4 driver with 
(A) or without (B) the addition of pure MG. The presence of MG could not be 
detected in the tested extract without the addition of pure MG. The arrows point 
for the detection of MG in the positive control, with the addition of pure MG to 







In this work we successfully generated transgenic Drosophila lines 
expressing the bifunctional enzyme MGSD. The expression of MGSD, at 
the protein level, was proved by immunoblot and confocal imaging 
analysis, using a specific antibody for this enzyme. Additionally, we 
demonstrated that the co-expression of MGSD promoted a beneficial effect 
in the ER stress induced by the expression of ninaEG69D in the 
photoreceptors. However, as we could not prove the in vivo biosynthesis 
and accumulation of MG in Drosophila tissues, we cannot conclude that 
MGSD is being expressed in a functionally active state. Also, we cannot 
be sure that the reduction of the ER stress levels promoted by the 
expression of MGSD was specifically induced by MG. The failure to 
prove the in vivo accumulation of MG did not allow us to proceed with the 
testing of the potential anti-aggregating and therapeutic properties of MG 
in Drosophila models for PD and HD. 
We can speculate about some of the reasons that could have 
contributed for the expression of MGSD in a functionally inactive state 
and/or for the failure of MGSD, even if expressed in a functional state, in 
synthesizing MG in Drosophila. One of the factors to take into 
consideration is the temperature for MSGD optimum activity, which has 
been determined as being 50 ºC [21]. Additionally, the optimum growth 
temperature of Dehalococcoides ethenogenes, the microorganism where 
the bifunctional enzyme MSGD was identified, is approximately 35 ºC 
[23]. These temperatures are different from the range of temperatures 
normally used to maintain Drosophila lines (18 ºC – 25 ºC). In order to 
minimize this difference, the Drosophila lines expressing MGSD used in 
our study were maintained at 28 ºC, the highest possible temperature to 
maintain healthy flies. Although the temperature used to cultivate our fly 
lines may have contributed for the improper function of MGSD, we 
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believe this did not constitute the determinant factor for the non-functional 
state of this enzyme and consequent failure in the production and 
accumulation of MG. Actually, in a previous study [15], it has been 
described the successful MG in vivo accumulation, in a genetically 
engineered yeast expressing MGSD grown at 30 ºC. This fact reinforces 
our opinion that other factors, beyond temperature, would have been more 
decisive to the failure in the accumulation of MG by our Drosophila 
transgenic lines. A possible reason may be the lack of proper machinery 
and/or physiological conditions in Drosophila cells for the correct folding 
necessary to produce an enzymatically active form of this enzyme. 
Another plausible reason can be related with the low levels in the 
Drosophila cells of 3-phosphate glycerate, the necessary substrate for the 
biosynthesis of MG by MGSD. Although this substrate is an intermediate 
of glycolysis, a universal energy pathway present in all organisms, it is 
possible that the occurrence of substrate channeling and formation of a 
metabolon, a very common and well characterized metabolic phenomenon 
[24], could have contributed to an inadequate metabolic environment for 
the in vivo biosynthesis of MG in Drosophila cells.  It is tempting to think 
that increasing the concentration 3-phosphate glycerate in the cytoplasm, 
for example through the genetic manipulation of the glycolytic pathway, 
would increase the quantity of this substrate available to diffuse to the 
active site of MGSD to be converted into MG. In order to test this 
hypothesis we induced the genetic knockdown of the enzyme involved in 
the immediately next step of the glycolytic pathway, in this case the 
phosphoglycero-mutase, by using a specific RNAi Drosophila line for this 
enzyme. We did this experiment in the Drosophila eye, by co-expressing 
MGSD with a UAS RNAi line for phosphoglycero-mutase (Pglym78). 
Unfortunately, once again, we could not detect the presence of MG in the 




5.5. Material and Methods 
Generation and maintenance of Drosophila stocks 
To generate UAS-MGSD, we sub-cloned the MGSD cDNA into 
pUAST using the BglII and Acc65I restriction sites. The primers used for 
PCR amplification of MGSD insert were: Forward – GCGAAGAT 
CTATGCGCATTGAAAGCCTG; Reverse – CGGTACCCTTATTCCATGGGCAG 
TATTATATCG. The transgenic flies were generated by BestGene, USA. We 
obtained 7 different UAS-MGSD lines. Four different drivers were 
obtained from the Bloomington Stock Center (Indiana University, 
Bloomington, IN, USA): elav-GAL4 (active in the entire nervous system 
under the control of the embryonic lethal abnormal vision promoter), 
nSyb-GAL4 (active in the entire nervous system, under the control of the 
Synaptobrevin promoter), Actin-GAL4 (active in the whole body), lGMR-
GAL4 (active in the eye, under the control of the glass multiple reporter). 
Drosophila stocks were maintained at 25 °C (or at 28 ºC for MGSD 
expression and MG production experiments) on standard cornmeal media 
in an incubator with a 12 h light/dark cycle. 
 
Immunohistochemistry and microscopy 
Eye imaginal discs preparations for confocal microscopy imaging 
were done as previously described [25]. Briefly, third instar larvae were 
collected and the eye imaginal discs were dissected and fixed in phosphate 
buffered saline (PBS) containing 4% paraformaldehyde. 
The photoreceptors were stained by incubation for 24 h at 4°C with 
rat anti-elav antibody (7E8A10 - Developmental Studies Hybridoma Bank 
– IA, USA) diluted 1:40 in PBST (1× PBS + 0.3% Triton X-100) 
containing 5% (v/v) normal goat serum. Three 10-min washes with PBST 
were done before incubation with a secondary anti-rat Cy5 (Jackson 
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ImmunoResearch), also diluted in PBST-containing 5% (v/v) normal goat 
serum. Eye imaginal discs were analyzed and images were collected using 
a LSM 710 Meta Zeiss confocal microscope. Images were acquired with a 
resolution of 1024 × 1024, with a slice thickness of 1 µm and a line-
average of 4. Z-projections were generated using ImageJ and the images 
were processed using Adobe Photoshop. 
 
Western Blot analysis 
Cell extracts from Drosophila heads (nSybGal4driver) were heated 
at 100 ºC for 10 min in Laemmili´s buffer (2% SDS). Protein separation 
was carried out by SDS-PAGE (10%). After electrophoresis, the proteins 
were transferred onto a polyvinylidene fluoride (PVDF) membrane 
(Millipore) with an electroblotting apparatus (Bio-Rad). The membranes 
were treated at room temperature with a blocking solution (TBS-T buffer: 
0.1% (v/v) Tween-20, 150 mM NaCl, 50 mM Tris–HCl, pH 7.5 plus 5% 
(w/v) BSA) during 1 hour. After blocking, the membranes were treated 
with a washing solution (phosphate-buffered saline containing 0.5% of 
milk and 0.1% of tween 20) followed by incubation overnight with the 
appropriate dilution of primary antibody (1:27000 for anti-MGSD) at room 
temperature in washing solution. The anti-MGSD was kindly supplied by 
Prof. H. Santos [22]. After overnight incubation at 4 °C, the membrane 
was washed three times with TBS-T buffer and probed with the 
appropriate secondary antibodies (anti-rabbit conjugated with horseradish 
peroxidase, GE healthcare), for 1 h at room temperature. Signals were 
revealed with the ECL Plus detection kit (Millipore, USA) and visualized 






Analysis of MG formation by thin layer chromatography 
Fly tissues (isolated heads or whole bodies) were frozen in liquid 
nitrogen and triturated with a mortar and pestle. Subsequently we 
proceeded with an ethanol-chloroform extraction by the method previously 
described [26]. 
Thin layer chromatography was performed on Silica Gel 60 plates 
(Merck) with a solvent system composed of chloroform, methanol, acetic 
acid, and water (30:50:8:4, v/v/v/v). MG was visualized by spraying with 
α-naphtholsulfuric acid solution followed by charring at 120 ºC. Pure MG 
was used for comparison [27]. 
 
NMR spectroscopy 
1H-NMR spectra were acquired on a Bruker Avance II 500 NMR 
spectrometer with a 5-mm broadband probe head with inverse detection. 
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6.1. Final discussion 
Here we provide a discussion of the main findings described in the 
previous research chapters and we also highlight some future perspectives. 
In this work, we developed new transgenic Drosophila models for 
PD and HD (Chapter I). The model for PD is based on the overexpression 
of EGFP-tagged versions of a wild-type and the A30P familiar mutant 
form of human α-syn. The HD model is based on the overexpression of 
mCherry-tagged versions of a wild-type (19Q) and a mutant (97Q) form of 
human Htt. Previous Drosophila models for PD based on the 
overexpression of  human α-syn, express this protein without fluorescent 
tags [1]. To the best of our knowledge, our transgenic UAS lines for PD 
are the only ones encoding fluorescent-tagged versions of α-syn, which 
constitutes a significant improvement that allows an efficient imaging of 
these proteins in vivo, avoiding possible artifacts derived from fixation of 
tissues and the use of antibodies. 
PD and HD are two common human neurodegenerative diseases 
with no cures available and associated to the malfunction of the basal 
ganglia, which clinically manifests in the motor dysfunction symptoms 
typically observed in patients. During the last two decades, the intense 
research in the genetic bases of these pathologies permitted the 
identification of loci that, when mutated, cause the disease. In PD, α-syn is 
one of the major molecular players, and in HD, Htt was identified as its 
monogenic cause. These proteins share some important molecular features, 
namely, they are both highly expressed in the brain and very 
prone-to-aggregate and to form intraneuronal protein inclusions. 
Furthermore, and very importantly, the exact biological function of α-syn 
and Htt remains unclear. In this study, using our Drosophila models, we 
were specifically interested in studying how the subcellular localization of 




development of PD and HD, respectively. Additionally, we aimed to study 
how these neuronal proteins interact at the functional and genetic levels. 
Using our newly established Drosophila model for PD, we 
investigated the molecular determinants of the subcellular localization of 
α-syn (Chapter II). Taking advantage of the Gal4/UAS system, we induced 
the targeted expression of the wild-type and the mutant A30P α-syn in the 
eye using the sGMR-Gal4 driver. We observed a differential phenotype for 
the two versions of α-syn, in terms of subcellular localization in the 
photoreceptors: while wild-type α-syn was enriched in pre-synaptic 
terminals, mutant α-syn was distributed throughout the cytoplasm of the 
photoreceptors, both in cell bodies and axons (Fig. 2.3). The synaptic 
enrichment of wild-type α-syn in Drosophila is consistent with the normal 
intracellular distribution of α-syn in the vertebrate nervous system [2-5]. 
Our observation that A30P α-syn loses this synaptic enrichment is coherent 
with a previous study observing a less efficient axonal transport of familiar 
mutant forms of α-syn in rat cortical neurons in culture [6]. The 
phenotypes observed in our Drosophila model were not a consequence of 
different expression levels (Fig. 2.4) or of different states and/or levels of 
aggregation (Fig. 2.5 and 2.6).  
The subsequent experiments performed in our study were delineated 
under the basis the hypothesis that the A30P missense mutation, 
responsible for familiar cases of PD, induces its neurotoxicity both by loss-
of-function and gain-of-toxicity mechanisms. The mislocalization and the 
depletion of mutant α-syn from the axonal terminals may hinder the 
normal biological functions of α-syn in the synapse, causing synaptic 
dysfunctions, namely abnormal neurotransmission. Additionally, gain-of 
toxicity mechanisms may be caused by an increase in the propensity of the 




other neuronal proteins, changing its specific neuronal partners and 
consequently affecting the normal functions of other neuronal proteins. 
In order to test our hypothesis we decided to identify the specific 
protein partners for the wild-type and A30P mutant versions of α-syn 
(Fig. 2.7). The results obtained were consistent with the eye phenotype 
observed in vivo. Most protein partners identified for wild-type α-syn, 
which we found to mainly accumulate in the synapse, were synaptic 
proteins and proteins involved in neurotransmission, while the interactome 
of the A30P mutant, which we found to lose this synaptic enrichment, was 
mostly associated to mitochondria and/or ribosomes (Table 2.1). 
Taking advantage of the list of specific protein partners for 
wild-type and mutant α-syn, we decided to test the effect of the specific 
removal of these protein interactors in the differential localization of wild-
type and A30P α-syn. The experimental approach chosen was to perform a 
reverse genetic RNAi screen in the genetic background of flies expressing 
the A30P mutant version of α-syn in the eye. Based on this genetic screen, 
we identified 3 candidate modulators of the subcellular localization of 
A30P α-syn: Tomosyn, Spaghetti Squash and Synaptotagmin 4 (Fig. 2.8). 
By demonstrating the existence of different specific neuronal partners for 
the wild-type and mutant version of α-syn and that some of these protein 
interactors can modulate the subcellular localization of α-syn, we could 
confirme the pertinence of our hypothesis, previously mentioned. 
However, and despite our work, a very important question persists: 
is the mislocalization of α-syn an early event contributing to the 
neurodegeneration associated to PD or a consequence of this 
neurodegenerative process?  The answer to this question is still unclear and 
more studies are needed to clarify this issue. The study and validation of 
Tomosyn, Spaghetti Squash and Synaptotagmin 4 as modulators of α-syn 




would be to prove the physical interaction between these proteins and 
A30P α-syn. Also, the modulatory effects of α-syn partners should be 
further evaluated in additional functional assays, such as climbing and 
survival assays, where the motor ability and mortality of flies would be 
evaluated. Additionally, we would like to expand this study to other 
neuronal populations, such as DA neurons, in order to determine if A30P 
mislocalization is universal – and therefore dependent on the A30P 
mutation – or if it depends on the cellular context – and therefore can be 
modulated by genetic or environmental factors. 
We believe the continuing of our work could contribute to the 
knowledge of the molecular mechanisms involved in PD, both in the 
familiar and in the sporadic forms. Also, this study could help to clarify the 
role of α-syn’s subcellular localization and the possibility of defective 
axonal transport of this protein being involved in PD pathogenesis. 
With our new Drosophila model for HD, we studied the role of the 
phosphorylation of the N-terminal domain of Htt in HD (Chapter III). 
We presented evidence suggesting that single phosphorylation 
events in the first 17 amino acids of the N-terminal domain (NT17) of Htt 
can modulate mutant Htt aggregation and neurotoxicity, depending on the 
biological context (Fig. 3.5, 3.6 and 3.7). Most of the studies on the 
therapeutic potential of NT17 phosphorylation have investigated the 
protective effect of double phosphorylation events at S13 and S16 residues 
[7, 8]. However, single phosphorylation events are more common than 
double phosphorylation events [9]. By demonstrating that single NT17 
phosphorylation events are sufficient to reduce the toxicity of mutant Htt, 
we provide evidences that a simpler and, probably more effective, 
approach may also have a therapeutic value. Because, the approach based 
on the double phosphorylation events would imply the overexpression of 




contribution in the complex path towards the discovery of an effective 
drug against HD. 
Furthermore, we aimed to identify some of the phosphatases 
involved in the dephosphorylation of NT17 residues, which may constitute 
a more promising therapeutic target in HD than the kinases.We found that 
the inhibition of specific protein phosphatases resulted in lower 
aggregation of mutant Htt (Fig. 3.3). Namely, the inhibition of Cdc25 
promoted a reduction of mutant Htt aggregation, both in human H4 cells 
and in Drosophila dopaminergic neurons (Fig. 3.3 and 3.4). We are 
currently interested in identifying the specific residues in the NT17 domain 
which are substrates of specific phosphatases that modulate mutant Htt 
aggregation. The reduction of mutant Htt aggregation induced by the 
downregulation of Cdc25 is not coherent with our results obtained with the 
phosphomimic mutants. At this point, we are not able to justify these 
discrepancies, but we think that one possible explanation could be related 
with the differences in the experimental approaches used. The 
overexpression of mutant Htt containing phosphomimic mutations 
simulates the extreme situation in which the whole pool of mutant Htt is 
constitutively phosphorylated, while the genetic knockdown of Cdc25 
inhibits the dephosphorylation promoted by this specific phosphatase, 
increasing the fraction of mutant Htt in the phosphorylated state but 
maintaining a mixed pool of mutant Htt in the phosphorylated and 
unphosphorylated states. The cell machinery involved in the maintenance 
of protein homeostasis, such as the ubiquitin–proteasome system, may be 
sensitive to these differences and induce different responses with different 
final outcomes, namely by targeting or not misfolded proteins to 
degradation and/or to form protein inclusions. 
We believe the findings described in this thesis may be relevant in 




event could provide a simpler and more efficient molecular target from a 
therapeutic point of view. We hope the continuing of this study and the 
successful identification of the specific phosphatases and the exact 
residues involved in the modulation of mutant Htt aggregation and 
neurotoxicity could consistently establish the NT17 as a very promising 
target in the search for new drugs for HD. 
Taking advantage of our new Drosophila models for PD and HD, 
we investigated the possible crosstalk between these neuropathologies 
(Chapter 4). This study arose from the hypothesis that the cellular and 
molecular mechanisms underlying PD and HD may overlap in the same 
neuronal cells, of the same patient. Proteins associated to human 
neuropathologies, which are very prone-to-aggregate, show the tendency 
to co-aggregate and sequester other neuronal proteins [11-13]. 
We studied the functional and genetic interaction of α-syn and Htt 
and besides showing that α-syn and mutant Htt can interact and 
co-aggregate when co-expressed in vivo (Fig. 4.1, 4.2, 4.3 and 4.4), we 
demonstrated the occurrence of synergistic deleterious actions of these 
proteins. Flies co-expressing α-syn and mutant Htt in the same neuronal 
tissues, showed an increased and more premature neurodegeneration 
(Fig. 4.5), accompanied by a strong deterioration of the motor function and 
a significant decrease in the life span (Fig. 4.6). 
Our results support the hypothesis that the co-occurrence of α-syn 
and mutant Htt in neuronal cells could affect disease progression and 
constitute a real risk for the triggering and co-evolution of pathogenic 
molecular mechanisms associated with PD and HD.  
Consistent with our results, postmortem analyses of HD brains 
showed that Htt inclusions were also immunoreactive for α-syn [14]. In 
fact, we believe a patient suffering from HD that an individual harboring 




co-developing some neuropathology related with the malfunction of α-syn. 
Htt aggregation could affect the normal function of aggregation-prone 
proteins like α-syn by sequestering them in HD inclusions. The 
observation that wild-type α-syn is mostly soluble in Drosophila neuronal 
tissues and only aggregates in the presence of mutant Htt further supports 
this hypothesis. 
Our results could explain why some patients diagnosed with HD or 
other neurodegenerative disease frequently show symptoms typically 
associated with other neuropathologies, such as PD or AD.  
Although the dysfunction of molecular pathways like the 
autophagy/lysosomal pathway or the disturbance of the normal axonal 
transport were not investigated in our Drosophila models for PD and HD, 
we think they should be addressed in future works. These mechanisms are 
involved in the development of neuropathologies associated with the 
accumulation of misfolded-proteins and it would be important to 
investigate if they have a causative relation with the phenotypes observed 
in our fly models. 
Finally, in this work, we aimed to demonstrate the utility of our 
Drosophila models for PD and HD in testing potential therapeutic 
compounds for these pathologies (chapter 5).  
The in vivo testing of candidate therapeutic compounds using 
animal models for human neurodegenerative may help not only in the 
selection of the most promising compounds for clinical trials, but also 
guide and inspire the design of new more effective drugs. 
A previous study from our collaborators demonstrated the protective 
effect of MG in a yeast model for PD [15]. We wanted to expand this 
study by investigating if we could reproduce the protective effect of MG in 




We successfully generated transgenic Drosophila lines expressing 
the bifunctional enzyme MGSD (Fig. 5.3) and demonstrated a beneficial 
effect of this enzyme in ninaEG69D-mediated ER stress (Fig. 5.4). However, 
we failed to prove the biosynthesis of MG in Drosophila in vivo, making 
impossible to conclude about the specificity of the MG effect.  
The substrate for MGSD is 3-phosphate glycerate, an intermediate 
of the universal energy pathway glycolysis. Because it is universal, we 
believe it could be possible to induce the in vivo biosynthesis of MG in 
Drosophila cells. However, several factors could have contributed for the 
non-accumulation of MG in Drosophila. The differences between the 
optimum temperature for the activity of MGSD (50 ºC) and the normal 
temperatures to cultivate flies (25 ºC), may be one of these factors. 
Alternative causes may be related with genetic and molecular determinants 
specific of Drosophila cells, which may lack the proper conditions for the 
correct folding of MGSD or may have low levels of some metabolites 
(namely, 3-phosphate glycerate) available to be converted into MG. 
Based on the tempting hypothesis that by manipulating the cellular 
concentration of metabolites involved in the biosynthesis of MGSD, such 
as 3-phosphate glycerate, we could increase the chances of successfully 
accumulate MG in Drosophila, we decided to genetically modify the 
glycolytic pathway. We knocked down phosphoglycero-mutase, the 
enzyme responsible for the catalysis of the glycolytic intermediate 
3-phosphate glycerate, the MGSD substrate, to 2-phosphate glycerate. This 
experiment was performed in the eye, using the sGMR-Gal4 driver. In 
future experiments, this same experimental approach should be tested in 
different tissues, which may offer specific genetic and molecular 
determinants that can be more advantageous for the biosynthesis of MG. 
We think our study supports a view where the mechanisms 




overlapped, at the cellular and molecular levels. In fact, from a list of 
top-ranked protein interactors of Htt in the mammalian brain, constituted 
by 17 proteins, 9 were also identified in our study as being α-syn’s 
interactors, further supporting the view of a possible strong proteomic 
crosstalk between PD and HD [16]. The continuing of the study of the 
interactomes associated to particular human neurodegenerative diseases, 
namely by characterizing the protein networks established in the neuronal 
cells affected, may help to clarify if and how the crosstalk between these 
pathologies occurs, as well as its relevance in their etiology and evolution. 
We hope our new Drosophila models for PD and HD may constitute 







1. Feany, M.B. and W.W. Bender, A Drosophila model of 
Parkinson's disease. Nature, 2000. 404(6776): p. 394-8. 
2. Maroteaux, L., J.T. Campanelli, and R.H. Scheller, Synuclein: a 
neuron-specific protein localized to the nucleus and presynaptic 
nerve terminal. J Neurosci, 1988. 8(8): p. 2804-15. 
3. Iwai, A., et al., The precursor protein of non-A beta component of 
Alzheimer's disease amyloid is a presynaptic protein of the central 
nervous system. Neuron, 1995. 14(2): p. 467-75. 
4. Jakes, R., M.G. Spillantini, and M. Goedert, Identification of two 
distinct synucleins from human brain. FEBS Lett, 1994. 345(1): p. 
27-32. 
5. Withers, G.S., et al., Delayed localization of synelfin (synuclein, 
NACP) to presynaptic terminals in cultured rat hippocampal 
neurons. Brain Res Dev Brain Res, 1997. 99(1): p. 87-94. 
6. Saha, A.R., et al., Parkinson's disease alpha-synuclein mutations 
exhibit defective axonal transport in cultured neurons. J Cell Sci, 
2004. 117(Pt 7): p. 1017-24. 
7. Gu, X., et al., Serines 13 and 16 are critical determinants of full-
length human mutant huntingtin induced disease pathogenesis in 
HD mice. Neuron, 2009. 64(6): p. 828-40. 
8. Mishra, R., et al., Serine Phosphorylation Suppresses Huntingtin 
Amyloid Accumulation by Altering Protein Aggregation 
Properties. J Mol Biol, 2012. 
9. Bustamante, M.B., et al., Detection of huntingtin exon 1 
phosphorylation by Phos-Tag SDS-PAGE: Predominant 
phosphorylation on threonine 3 and regulation by IKKbeta. 
Biochem Biophys Res Commun, 2015. 463(4): p. 1317-22. 
10. Thompson, L.M., et al., IKK phosphorylates Huntingtin and 
targets it for degradation by the proteasome and lysosome. J Cell 
Biol, 2009. 187(7): p. 1083-99. 
11. Sajjad, M.U., et al., DJ-1 modulates aggregation and pathogenesis 
in models of Huntington's disease. Hum Mol Genet, 2014. 23(3): 
p. 755-66. 
12. Blum, D., et al., Mutant huntingtin alters Tau phosphorylation and 
subcellular distribution. Hum Mol Genet, 2014. 
13. Badiola, N., et al., Tau Enhances alpha-Synuclein Aggregation 
and Toxicity in Cellular Models of Synucleinopathy. PLoS One, 
2011. 6(10): p. e26609. 
14. Charles, V., et al., Alpha-synuclein immunoreactivity of huntingtin 
polyglutamine aggregates in striatum and cortex of Huntington's 
disease patients and transgenic mouse models. Neurosci Lett, 




15. Faria, C., et al., Inhibition of formation of alpha-synuclein 
inclusions by mannosylglycerate in a yeast model of Parkinson's 
disease. Biochim Biophys Acta, 2013. 1830(8): p. 4065-72. 
16. Shirasaki, D.I., et al., Network organization of the huntingtin 
proteomic interactome in mammalian brain. Neuron, 2012. 75(1): 
p. 41-57. 
  
 
 
 
 
 
 
 
